CA2273002A1 - Immunotherapeutic imides/amides as pde iv and tnf inhibitors - Google Patents
Immunotherapeutic imides/amides as pde iv and tnf inhibitors Download PDFInfo
- Publication number
- CA2273002A1 CA2273002A1 CA002273002A CA2273002A CA2273002A1 CA 2273002 A1 CA2273002 A1 CA 2273002A1 CA 002273002 A CA002273002 A CA 002273002A CA 2273002 A CA2273002 A CA 2273002A CA 2273002 A1 CA2273002 A1 CA 2273002A1
- Authority
- CA
- Canada
- Prior art keywords
- carbon atoms
- alkyl
- substituted
- amino
- methoxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000003949 imides Chemical class 0.000 title abstract description 4
- 150000001408 amides Chemical class 0.000 title description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title description 2
- 230000001024 immunotherapeutic effect Effects 0.000 title 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 title 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 101
- -1 amide ethers Chemical class 0.000 claims abstract description 52
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 32
- 230000010076 replication Effects 0.000 claims abstract description 7
- 125000004849 alkoxymethyl group Chemical group 0.000 claims abstract description 5
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims abstract description 5
- 241001430294 unidentified retrovirus Species 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 58
- 150000001875 compounds Chemical class 0.000 claims description 23
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000001475 halogen functional group Chemical group 0.000 claims description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 15
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims description 8
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 4
- 239000005977 Ethylene Substances 0.000 claims description 4
- 125000004442 acylamino group Chemical group 0.000 claims description 4
- 125000004450 alkenylene group Chemical group 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000005293 bicycloalkoxy group Chemical group 0.000 claims description 4
- 150000001602 bicycloalkyls Chemical group 0.000 claims description 4
- 125000005724 cycloalkenylene group Chemical group 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 4
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- 125000005001 aminoaryl group Chemical group 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 abstract description 8
- 102000004127 Cytokines Human genes 0.000 abstract description 7
- 206010040070 Septic Shock Diseases 0.000 abstract description 6
- 206010006895 Cachexia Diseases 0.000 abstract description 5
- NTWLARBDJFXJNZ-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-3-hydroxypropyl]isoindole-1,3-dione Chemical group C1=C(OC)C(OC)=CC=C1C(CCO)N1C(=O)C2=CC=CC=C2C1=O NTWLARBDJFXJNZ-UHFFFAOYSA-N 0.000 abstract description 4
- 206010003246 arthritis Diseases 0.000 abstract description 4
- 206010014824 Endotoxic shock Diseases 0.000 abstract description 3
- 208000006673 asthma Diseases 0.000 abstract description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 2
- 150000001298 alcohols Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- 108700012920 TNF Proteins 0.000 description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 239000007787 solid Substances 0.000 description 44
- 239000000243 solution Substances 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 28
- 239000012044 organic layer Substances 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000000725 suspension Substances 0.000 description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- 229910052739 hydrogen Inorganic materials 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 239000004480 active ingredient Substances 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 241000725303 Human immunodeficiency virus Species 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 15
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 14
- 235000019341 magnesium sulphate Nutrition 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 13
- 238000004587 chromatography analysis Methods 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 208000030507 AIDS Diseases 0.000 description 7
- 101150041968 CDC13 gene Proteins 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 238000001994 activation Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 208000031886 HIV Infections Diseases 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- UALOHNUOSXTBDG-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-3-hydroxypropyl]isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CCO)N2C(C3=CC=CC=C3C2=O)=O)=C1 UALOHNUOSXTBDG-UHFFFAOYSA-N 0.000 description 5
- OJRXGWPSOSXIDE-UHFFFAOYSA-N 3-amino-3-(3-ethoxy-4-methoxyphenyl)propan-1-ol Chemical compound CCOC1=CC(C(N)CCO)=CC=C1OC OJRXGWPSOSXIDE-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- HEMHJVSKTPXQMS-DYCDLGHISA-M Sodium hydroxide-d Chemical compound [Na+].[2H][O-] HEMHJVSKTPXQMS-DYCDLGHISA-M 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- UDHNWYRORFIKCM-UHFFFAOYSA-N methyl 3-amino-3-(3-cyclopentyloxy-4-methoxyphenyl)propanoate Chemical compound COC(=O)CC(N)C1=CC=C(OC)C(OC2CCCC2)=C1 UDHNWYRORFIKCM-UHFFFAOYSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- JWJVWOATGIGNEO-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-3-hydroxypropyl]-3h-isoindol-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(CCO)N1C(=O)C2=CC=CC=C2C1 JWJVWOATGIGNEO-UHFFFAOYSA-N 0.000 description 3
- MQQYGKIKWAOMFR-UHFFFAOYSA-N 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-3-hydroxypropyl]isoindole-1,3-dione Chemical compound COC1=CC=C(C(CCO)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 MQQYGKIKWAOMFR-UHFFFAOYSA-N 0.000 description 3
- FGCXSFRGPCUBPW-UHFFFAOYSA-N 3-amino-3-(3,4-dimethoxyphenyl)propanoic acid Chemical compound COC1=CC=C(C(N)CC(O)=O)C=C1OC FGCXSFRGPCUBPW-UHFFFAOYSA-N 0.000 description 3
- JTQCVSLHXUMLGF-UHFFFAOYSA-N 3-azaniumyl-3-(3-ethoxy-4-methoxyphenyl)propanoate Chemical compound CCOC1=CC(C([NH3+])CC([O-])=O)=CC=C1OC JTQCVSLHXUMLGF-UHFFFAOYSA-N 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 3
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 208000001388 Opportunistic Infections Diseases 0.000 description 3
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
- 210000005091 airway smooth muscle Anatomy 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- QRYPKORMUWBUPW-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-3-methoxypropyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C(CCOC)C1=CC=C(OC)C(OC)=C1 QRYPKORMUWBUPW-UHFFFAOYSA-N 0.000 description 2
- FQTVQRIDWFXPAE-UHFFFAOYSA-N 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-3-methoxypropyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C(CCOC)C(C=1)=CC=C(OC)C=1OC1CCCC1 FQTVQRIDWFXPAE-UHFFFAOYSA-N 0.000 description 2
- ASNZVQDEHOHTSG-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-3-methoxypropyl]isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CCOC)N2C(C3=CC=CC=C3C2=O)=O)=C1 ASNZVQDEHOHTSG-UHFFFAOYSA-N 0.000 description 2
- MXNRLIIVMDNYJN-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-3-phenylmethoxypropyl]isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CCOCC=2C=CC=CC=2)N2C(C3=CC=CC=C3C2=O)=O)=C1 MXNRLIIVMDNYJN-UHFFFAOYSA-N 0.000 description 2
- FAYCVXFLAICNJN-UHFFFAOYSA-N 3-amino-3-(3-cyclopentyloxy-4-methoxyphenyl)propan-1-ol Chemical compound COC1=CC=C(C(N)CCO)C=C1OC1CCCC1 FAYCVXFLAICNJN-UHFFFAOYSA-N 0.000 description 2
- RGICSXKVRUULGR-UHFFFAOYSA-N 3-amino-3-(3-cyclopentyloxy-4-methoxyphenyl)propanoic acid Chemical compound COC1=CC=C(C(N)CC(O)=O)C=C1OC1CCCC1 RGICSXKVRUULGR-UHFFFAOYSA-N 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000019664 bone resorption disease Diseases 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- VRHAQNTWKSVEEC-UHFFFAOYSA-N ethyl 1,3-dioxoisoindole-2-carboxylate Chemical compound C1=CC=C2C(=O)N(C(=O)OCC)C(=O)C2=C1 VRHAQNTWKSVEEC-UHFFFAOYSA-N 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- DPDHEFCLHFWWJB-UHFFFAOYSA-N methyl 3-amino-3-(3,4-dimethoxyphenyl)propanoate Chemical compound COC(=O)CC(N)C1=CC=C(OC)C(OC)=C1 DPDHEFCLHFWWJB-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002947 procoagulating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108091006106 transcriptional activators Proteins 0.000 description 2
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 2
- 229940100445 wheat starch Drugs 0.000 description 2
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- NIRRAUQSXSIQCM-UHFFFAOYSA-N 2-(1-cyclohexyl-3-methoxypropyl)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C(CCOC)C1CCCCC1 NIRRAUQSXSIQCM-UHFFFAOYSA-N 0.000 description 1
- SURVJBLCJYZARJ-UHFFFAOYSA-N 2-[1-(3,4-diethoxyphenyl)-3-(pyridin-3-ylmethoxy)propyl]-3h-isoindol-1-one Chemical compound C1=C(OCC)C(OCC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CCOCC1=CC=CN=C1 SURVJBLCJYZARJ-UHFFFAOYSA-N 0.000 description 1
- ABWKQRZAXZSENY-UHFFFAOYSA-N 2-[1-(3,4-diethoxyphenyl)-3-(pyridin-3-ylmethoxy)propyl]isoindole-1,3-dione Chemical compound C1=C(OCC)C(OCC)=CC=C1C(N1C(C2=CC=CC=C2C1=O)=O)CCOCC1=CC=CN=C1 ABWKQRZAXZSENY-UHFFFAOYSA-N 0.000 description 1
- YZVHNZUSOUUPIF-UHFFFAOYSA-N 2-[1-(3,4-diethoxyphenyl)-3-ethoxypropyl]-3h-isoindol-1-one Chemical compound C1C2=CC=CC=C2C(=O)N1C(CCOCC)C1=CC=C(OCC)C(OCC)=C1 YZVHNZUSOUUPIF-UHFFFAOYSA-N 0.000 description 1
- OBKIJVASAALGIC-UHFFFAOYSA-N 2-[1-(3,4-diethoxyphenyl)-3-ethoxypropyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C(CCOCC)C1=CC=C(OCC)C(OCC)=C1 OBKIJVASAALGIC-UHFFFAOYSA-N 0.000 description 1
- BIUXHKWMYCCXFD-UHFFFAOYSA-N 2-[1-(3,4-diethoxyphenyl)-3-methoxypropyl]isoindole-1,3-dione Chemical compound C1=C(OCC)C(OCC)=CC=C1C(CCOC)N1C(=O)C2=CC=CC=C2C1=O BIUXHKWMYCCXFD-UHFFFAOYSA-N 0.000 description 1
- WGPJSGUADVYEMG-UHFFFAOYSA-N 2-[1-(3,4-diethylcyclohexyl)-3-methoxypropyl]isoindole-1,3-dione Chemical compound C1C(CC)C(CC)CCC1C(CCOC)N1C(=O)C2=CC=CC=C2C1=O WGPJSGUADVYEMG-UHFFFAOYSA-N 0.000 description 1
- LEMRBPKYXRBPMS-UHFFFAOYSA-N 2-[1-(3,4-diethylphenyl)-3-hydroxypropyl]isoindole-1,3-dione Chemical compound C1=C(CC)C(CC)=CC=C1C(CCO)N1C(=O)C2=CC=CC=C2C1=O LEMRBPKYXRBPMS-UHFFFAOYSA-N 0.000 description 1
- PEQDKCNUZDVHQV-UHFFFAOYSA-N 2-[1-(3,4-diethylphenyl)-3-methoxypropyl]isoindole-1,3-dione Chemical compound C1=C(CC)C(CC)=CC=C1C(CCOC)N1C(=O)C2=CC=CC=C2C1=O PEQDKCNUZDVHQV-UHFFFAOYSA-N 0.000 description 1
- CFGVKYUFXMMFEN-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-2-hydroxyethyl]isoindole-1,3-dione Chemical compound C1=C(OC)C(OC)=CC=C1C(CO)N1C(=O)C2=CC=CC=C2C1=O CFGVKYUFXMMFEN-UHFFFAOYSA-N 0.000 description 1
- QXAGUSKCPCOMFS-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-2-methoxyethyl]-3h-isoindol-1-one Chemical compound C1C2=CC=CC=C2C(=O)N1C(COC)C1=CC=C(OC)C(OC)=C1 QXAGUSKCPCOMFS-UHFFFAOYSA-N 0.000 description 1
- UWBVXCHUKULWAX-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-2-methoxyethyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C(COC)C1=CC=C(OC)C(OC)=C1 UWBVXCHUKULWAX-UHFFFAOYSA-N 0.000 description 1
- DMBIWHRHUANOQN-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-3-(pyridin-3-ylmethoxy)propyl]-3h-isoindol-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CCOCC1=CC=CN=C1 DMBIWHRHUANOQN-UHFFFAOYSA-N 0.000 description 1
- NAGKNLYKRHXBBC-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-3-(pyridin-3-ylmethoxy)propyl]isoindole-1,3-dione Chemical compound C1=C(OC)C(OC)=CC=C1C(N1C(C2=CC=CC=C2C1=O)=O)CCOCC1=CC=CN=C1 NAGKNLYKRHXBBC-UHFFFAOYSA-N 0.000 description 1
- GXVUEMYFPGQBQF-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-3-ethoxypropyl]-3h-isoindol-1-one Chemical compound C1C2=CC=CC=C2C(=O)N1C(CCOCC)C1=CC=C(OC)C(OC)=C1 GXVUEMYFPGQBQF-UHFFFAOYSA-N 0.000 description 1
- PXYNITJRLDAHOM-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-3-ethoxypropyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C(CCOCC)C1=CC=C(OC)C(OC)=C1 PXYNITJRLDAHOM-UHFFFAOYSA-N 0.000 description 1
- KCWUSICDMKMHLA-UHFFFAOYSA-N 2-[1-(3,4-dipropylphenyl)-3-hydroxypropyl]-3h-isoindol-1-one Chemical compound C1=C(CCC)C(CCC)=CC=C1C(CCO)N1C(=O)C2=CC=CC=C2C1 KCWUSICDMKMHLA-UHFFFAOYSA-N 0.000 description 1
- DBWODBMGDKIQOM-UHFFFAOYSA-N 2-[1-(3,4-dipropylphenyl)-3-hydroxypropyl]isoindole-1,3-dione Chemical compound C1=C(CCC)C(CCC)=CC=C1C(CCO)N1C(=O)C2=CC=CC=C2C1=O DBWODBMGDKIQOM-UHFFFAOYSA-N 0.000 description 1
- DGMIJGYEFXXNEO-UHFFFAOYSA-N 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-3-methoxypropyl]-4-hydroxyisoindole-1,3-dione Chemical compound O=C1C2=CC=CC(O)=C2C(=O)N1C(CCOC)C(C=1)=CC=C(OC)C=1OC1CCCC1 DGMIJGYEFXXNEO-UHFFFAOYSA-N 0.000 description 1
- UNPSPRSOPVCYHJ-UHFFFAOYSA-N 2-[3-methoxy-1-(4-methoxy-3-propan-2-yloxyphenyl)propyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C(CCOC)C1=CC=C(OC)C(OC(C)C)=C1 UNPSPRSOPVCYHJ-UHFFFAOYSA-N 0.000 description 1
- LGAZLBWJAFUDST-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C1=C(OC)C(OC)=CC=C1C(CC(O)=O)N1C(=O)C2=CC=CC=C2C1 LGAZLBWJAFUDST-UHFFFAOYSA-N 0.000 description 1
- LIVKGYIUNICCIZ-UHFFFAOYSA-N 3-amino-3-(3,4-dimethoxyphenyl)propan-1-ol Chemical compound COC1=CC=C(C(N)CCO)C=C1OC LIVKGYIUNICCIZ-UHFFFAOYSA-N 0.000 description 1
- FZFWPURYSWKIRT-UHFFFAOYSA-N 3-cyclopentyloxy-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1OC1CCCC1 FZFWPURYSWKIRT-UHFFFAOYSA-N 0.000 description 1
- VAMZHXWLGRQSJS-UHFFFAOYSA-N 3-ethoxy-4-methoxybenzaldehyde Chemical compound CCOC1=CC(C=O)=CC=C1OC VAMZHXWLGRQSJS-UHFFFAOYSA-N 0.000 description 1
- HQTWGXLJERTXOA-UHFFFAOYSA-N 4-amino-2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-3-methoxypropyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC(N)=C2C(=O)N1C(CCOC)C(C=1)=CC=C(OC)C=1OC1CCCC1 HQTWGXLJERTXOA-UHFFFAOYSA-N 0.000 description 1
- MAGYRYWUUIOFSU-UHFFFAOYSA-N 4-amino-2-[3-methoxy-1-(4-methoxy-3-propan-2-yloxyphenyl)propyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC(N)=C2C(=O)N1C(CCOC)C1=CC=C(OC)C(OC(C)C)=C1 MAGYRYWUUIOFSU-UHFFFAOYSA-N 0.000 description 1
- WBDHMGNVRUXWPK-UHFFFAOYSA-N 4-amino-2-[3-methoxy-1-(4-methoxy-3-propoxyphenyl)propyl]isoindole-1,3-dione Chemical compound C1=C(OC)C(OCCC)=CC(C(CCOC)N2C(C3=C(N)C=CC=C3C2=O)=O)=C1 WBDHMGNVRUXWPK-UHFFFAOYSA-N 0.000 description 1
- SHXJIQRTJWVANH-UHFFFAOYSA-N 4-hydroxy-2-[3-methoxy-1-(4-methoxy-3-propan-2-yloxyphenyl)propyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC(O)=C2C(=O)N1C(CCOC)C1=CC=C(OC)C(OC(C)C)=C1 SHXJIQRTJWVANH-UHFFFAOYSA-N 0.000 description 1
- KWWCNLKDUSFGMY-UHFFFAOYSA-N 4-hydroxy-2-[3-methoxy-1-(4-methoxy-3-propoxyphenyl)propyl]isoindole-1,3-dione Chemical compound C1=C(OC)C(OCCC)=CC(C(CCOC)N2C(C3=C(O)C=CC=C3C2=O)=O)=C1 KWWCNLKDUSFGMY-UHFFFAOYSA-N 0.000 description 1
- ROFZMKDROVBLNY-UHFFFAOYSA-N 4-nitro-2-benzofuran-1,3-dione Chemical compound [O-][N+](=O)C1=CC=CC2=C1C(=O)OC2=O ROFZMKDROVBLNY-UHFFFAOYSA-N 0.000 description 1
- RVWGXOSOJNKGTP-UHFFFAOYSA-N 5-amino-2-[3-methoxy-1-(4-methoxy-3-propan-2-yloxyphenyl)propyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=C(N)C=C2C(=O)N1C(CCOC)C1=CC=C(OC)C(OC(C)C)=C1 RVWGXOSOJNKGTP-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- MFIOADVUUXNTEN-UHFFFAOYSA-N C1(CC=2C(C(N1C(CCOC)C1=CC(=C(C=C1)OC)OC1CCCC1)=O)=CC=CC2)=O Chemical compound C1(CC=2C(C(N1C(CCOC)C1=CC(=C(C=C1)OC)OC1CCCC1)=O)=CC=CC2)=O MFIOADVUUXNTEN-UHFFFAOYSA-N 0.000 description 1
- LEVDVJHLHPZWOI-UHFFFAOYSA-N C1=C(OC)C(OCCC)=CC(C(CCOC)N2C(C3=CC=CC=C3CC2=O)=O)=C1 Chemical compound C1=C(OC)C(OCCC)=CC(C(CCOC)N2C(C3=CC=CC=C3CC2=O)=O)=C1 LEVDVJHLHPZWOI-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 102100037355 Chromosome alignment-maintaining phosphoprotein 1 Human genes 0.000 description 1
- 206010010755 Conjunctivitis viral Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010020164 HIV infection CDC Group III Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 description 1
- 101000880066 Homo sapiens Chromosome alignment-maintaining phosphoprotein 1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 1
- WPJHTEPPXOAOQL-UHFFFAOYSA-N NC1=C2C(C(=O)N(C2=O)C(CCOC)C2=CC(=C(C=C2)OC)OCC)=CC=C1.O=C1N(CC2=CC=CC=C12)C(CCOC)C1=CC(=C(C=C1)CC)OCC Chemical compound NC1=C2C(C(=O)N(C2=O)C(CCOC)C2=CC(=C(C=C2)OC)OCC)=CC=C1.O=C1N(CC2=CC=CC=C12)C(CCOC)C1=CC(=C(C=C1)CC)OCC WPJHTEPPXOAOQL-UHFFFAOYSA-N 0.000 description 1
- RHHJRYHPRHKFKD-UHFFFAOYSA-N O=C1CC2=CC=CC=C2C(=O)N1C(CCOC)C1=CC=C(OC)C(OC(C)C)=C1 Chemical compound O=C1CC2=CC=CC=C2C(=O)N1C(CCOC)C1=CC=C(OC)C(OC(C)C)=C1 RHHJRYHPRHKFKD-UHFFFAOYSA-N 0.000 description 1
- SQJJCGFRDVGMEC-UHFFFAOYSA-N O=C1N(CC2=CC=CC=C12)C(CCOC)C1=CC(=C(C=C1)OC)OC1CCCC1 Chemical compound O=C1N(CC2=CC=CC=C12)C(CCOC)C1=CC(=C(C=C1)OC)OC1CCCC1 SQJJCGFRDVGMEC-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102100026966 Thrombomodulin Human genes 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 208000005914 Viral Conjunctivitis Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000713325 Visna/maedi virus Species 0.000 description 1
- 102100029477 Vitamin K-dependent protein C Human genes 0.000 description 1
- 101710193900 Vitamin K-dependent protein C Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 108010009896 bone resorption factor Proteins 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000005796 circulatory shock Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000009791 fibrotic reaction Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-N methoxyacetic acid Chemical compound COCC(O)=O RMIODHQZRUFFFF-UHFFFAOYSA-N 0.000 description 1
- NJWNMPYFTMYYDX-UHFFFAOYSA-N methyl 3-amino-3-(3-ethoxy-4-methoxyphenyl)propanoate Chemical compound CCOC1=CC(C(N)CC(=O)OC)=CC=C1OC NJWNMPYFTMYYDX-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000007302 negative regulation of cytokine production Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
Abstract
Novel imide/amide ethers and alcohols having formula (I) wherein R2 is -H, alkyl of 1 to 8 carbon atoms, benzy, pyridylmethyl, or alkoxymethyl; R4 is -CX-, CH2- or -CH2CX-; X is O or S; and, n is 0, 1, 2, or 3, are inhibitors of cytokines including tumor necrosis factor .alpha. and can be used to combat cachexia, endotoxic shock, arthritis, asthma, and retrovirus replication. A typical embodiment is 3-phthalimido-3-(3',4'-dimethoxyphenyl)propan-1-ol.
Description
This application is a continuation-in-part of U.S. Application Serial Number 08/366,667, filed December 30, 1994, which is pending.
BACKGROUND OF THE INVENTION
The present invention relates to a method of reducing levels of TNFa and inhibiting phosphodiesterase in a mammal and to compounds and compositions useful therein.
TNFa, or tumor necrosis factor a, is a cytokine which is released primarily by mononuclear phagocytes in response to various immunostimulators. When administered to animals or humans it causes inflammation, fever, cardiovascular effects, hemorrhage, coagulation and acute phase responses similar to those seen during acute infections and shock states.
Excessive or unregulated TNFa production has been implicated in a number of disease conditions. These include endotoxemia and/or toxic shock syndrome {Tracey et al., Nature 330, 662-664 (1987) and Hinshaw et al., Circ. Shock 30, 279-292 (1990)}; cachexia {Dezube et al., Lancet) 335(8690), 662 (1990)}; and Adult Respiratory Distress Syndrome where TNFa concentration in excess of 12,000 pg/milliliter have been detected in pulmonary aspirates from ARDS patients {Millar et al., Lancet 2(8665), 712-714 (1989)}. Systemic infusion of recombinant TNFa also resulted in changes typically seen in ARDS {Ferrai-Baliviera et al., Arch. Surg. 124(12), 1400-1405(1989)}.
TNFa appears to be involved in bone resorption diseases, including arthritis where it has been determined that when activated, leukocytes will produce a bone-resorbing activity, and data suggest that TNFa contributes to this activity. {Bertolini et al., Nature 319, 516-518 (1986) and Johnson et al., Endocrinology 124(3), 1424-1427 (1989).} It has been determined that TNFa stimulates bone resorption and inhibits bone formation in vitro and in vivo through stimulation of osteoclast formation and activation combined with inhibition of osteoblast function. Although TNFa may be involved in many bone resorption diseases, including arthritis, the most compelling link with disease is the association between production of TNFa by tumor or host tissues and malignancy associated hypercalcemia {Calci. Tissue Int. (US) 46(Suppl.), S3-10 (1990)}. In Graft versus Host Reaction, increased serum TNFa levels have been associated with major complication following acute allogenic bone marrow transplants {Holler et al., Blood, 75(4), 1011-1016 (1990)}.
Cerebral malaria is a lethal hyperacute neurological syndrome associated with high blood levels of TNFa and the most severe complication occurring in malaria patients.
Levels of serum TNFa correlated directly with the severity of disease and the prognosis in patients with acute malaria attacks {Grau et al., N Engl. J. Med. 320(24), 1586-1591 (1989)}.
TNFa also plays a role in the area of chronic pulmonary inflammatory diseases.
The deposition of silica particles leads to silicosis, a disease of progressive respiratory failure caused by a fibrotic reaction. Antibody to TNFa completely blocked the silica-induced lung fibrosis in mice {Pignet et al., Nature, 344:245-247 (1990)}. High levels of TNFa production (in the serum and in isolated macrophages) have been demonstrated in animal models of silica and asbestos induced fibrosis {Bissonnette et al., Inflammation 13(3), 329-339 (1989)}. Alveolar macrophages from pulmonary sarcoidosis patients have also been found to spontaneously release massive quantities of TNFa as compared with macrophages from normal donors {Baughman et al., J. Lab.
Clin. Med.
115(1). 36-42 (1990)}.
TNFa is also implicated in the inflammatory response which follows reperfusion, called reperfusion injury, and is a major cause of tissue damage after loss of blood flow {Vedder et al., PNAS 87, 2643-2646 (1990)}. TNFa also alters the properties of endothelial cells and has various pro-coagulant activities, such as producing an increase in tissue factor pro-coagulant activity and suppression of the anticoagulant protein C pathway as well as down-regulating the expression of thrombomodulin {Sherry et al., J. Cell Biol. 107, 1269-1277 (1988)}. TNFa has pro-inflammatory activities which together with its early production (during the initial stage of an inflammatory event) make it a likely mediator of tissue injury in several important disorders including but not limited to, myocardial infarction, stroke and circulatory shock. Of specific importance may be TNFa-induced expression of adhesion molecules, such as intercellular adhesion molecule (ICAM) or endothelial leukocyte adhesion molecule (ELAM) on endothelial cel Is { Munro et al. , Am.
J. Path. 13~( 1 ), 121-132 (1989)}.
Moreover. it now is known that TNFa is a potent activator of retrovirus replication including activation of HIV-1. {Duh et al., Proc. Nat. Acad Sci. 86, 5974-X978 (1989);
Poll et al., Proc: Nat.
Acad. Sci. 87, 782-785 (1990); Monto et al., Blood 79, 2670 (1990); Clouse et al., J. Immunol. 142.
431-43 8 ( 1989): Poll et al., AIDS Res. Hum. Retrovirus, 191-197 ( 1992) } .
AIDS results from the infection of T lymphocytes with Human Immunodeficiency Virus (HIV). At least three types or strains of HIV have been identified, i.e., HIV-1, HIV-2 and HIV-3. As a consequence of HIV
infection, T-cell mediated immunity is impaired and infected individuals manifest severe opportunistic infections and/or unusual neoplasms. HIV entry into the T
lymphocyte requires T lym-phocy~te activation. Other viruses, such as HIV-1, HIV-2 infect T lymphocytes after T cell activation and such virus protein expression and/or replication is mediated or maintained by such T cell activa-tion. Once an activated T lymphocyte is infected with HIV, the T lymphocyte must continue to be maintained in an activated state to permit HIV gene expression and/or HIV
replication. Cytokines, specifically TNFa, are implicated in activated T-cell mediated HIV protein expression and/or virus replication by playing a role in maintaining T lymphocyte activation.
Therefore, interference with cyokine activity such as by prevention or inhibition of cyokine production.
notably TNFa, in an HIV-infected individual aids in limiting the maintenance of T lymphocyte caused by HIV infection.
Monocytes, macrophages, and related cells, such as kupffer and glial cells, have also been implicated in maintenance of the HIV infection. These cells, like T cells, are targets for viral replication and the level of viral replication is dependent upon the activation state of the cells.
{Rosenberg et al., The Immunopathogenesis ofHIVlnfection, Advances in Immunology, 57 (1989)}.
Cytokines, such as TNFa, have been shown to activate HIV replication in monocytes andlor macrophages {Poli et al. Proc. Natl. Acad. Sci., 87, 782-784 (1990)}, therefore, prevention or inhibition of cytokine production or activity aids in limiting HIV progression as stated above for T
cells. Additional studies have identified TNFa as a common factor in the activation of HIV in vitro and has provided a clear mechanism of action via a nuclear regulatory protein found in the cytoplasm of cells (Osborn, et al. , PAPAS 86, 2336-2340). This evidence suggests that a reduction of TNFa synthesis may have an antiviral effect in HIV infections, by reducing the transcription and thus virus production.
HIV viral replication of latent HIV in T cell and macrophage lines can be induced by TNFa {Folks et al., PNAS 86, 2365-2368 (1989)}. A molecular mechanism for the virus inducing activity is suggested by TNFa's ability to activate a gene regulatory protein (NFxB) found in the cytoplasm of cells, which promotes HIV replication through binding to a viral regulatory gene sequence (LTR) {Osborn et al., PNAS 86, 2336-2340 (1989)}. TNFa in AIDS and cancer associated cachexia is sug-Bested by elevated semen TNFa and high levels of spontaneous TNFa production in peripheral blood monocytes from patients { Wright et al. J. Immunol. 141(1), 99-104 (1988)}.
{Eur J. Gastroen Hepat, 6_(9), 821-829 (1994)}. {J. Exp. Med., 1121-1227 (1988)}.
TNFa has been implicated in various roles with other viral infections, such as the cytomegalia virus (CMV), influenza virus, adenovirus, and the herpes family of viruses for similar reasons as those noted.
Preventing or inhibiting the production or action of TNFa is, therefore.
predicted to be a potent therapeutic strategy for many inflammatory, infectious, immunological or malignant diseases.
These include but are not restricted to septic shock. sepsis, endotoxic shock, hemodynamic shock and sepsis syndrome, post ischemic reperfusion injury, malaria, mycobacterial infection. meningitis, psoriasis, congestive heart failure, fibrotic disease, cachexia, graft rejection, cancer, autoimmune disease, opportunistic infections in AIDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, other arthritic conditions, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, systemic lupus erythrematosis, ENL in leprosy, asthma, radiation damage, and hyperoxic alveolar injury. Efforts directed to the suppression of the effects of TNFa have ranged from the utilization of steroids such as dexamethasone and prednisolone to the use of both polyclonal and monoclonal antibodies {Beutler et al., Science 234, 470-474 (1985); WO 92/11383}.
(Clinical.and Experimental Rheumatology 1993., ~ (Suppl. 8), 5173-5170. (PNAS
1992, 89, 9784-88). (Annals of the Rheumatic Diseases 1990, 4~, 480-486).
The nuclear factor xB (NFxB) is a pleiotropic transcriptional activator (Lenardo, et al. Cell 1989, 58, 227-29). NFxB has been implicated as a transcriptional activator in a variety of disease and inflammatory states and is thought to regulate cytokine levels including but nit limited to TNFa and also to be an activator of HIV transcription (Dbaibo, et al. J. Biol.
Chem. 1993, 17762-66; Duh et al. Proc. Natl. Acad. Sci. 1989, 86, 5974-78; Bachelerie et al. Nature 1991, 350, 709-1?; Boswas et al. J.. Acquired Immune Deficiency Syndrome 1993, 6, 778-786; Suzuki et al.
Biochcm. And Biophys. Res. Comm. 1993, 193, 277-83; Suzuki et al. Biochem. And Biophys. Res Comm. 1992, 189. 1709-1 ~; Suzuki et al. Biochem. Mol. Bio. Int. 1993, 3 I (4), 693-700;
Shakhov et al. 1990, 171, 35-47; and Staal et al. Proc. Natl. Acad. Sci. USA 1990, 87, 9943-47). Thus, inhibition of NFxB
binding can regulate transcription of cytokine genes) and through this modulation and other mechanisms be useful in the inhibition of a multitude of disease states. The compounds claimed in this patent can inhibit the action of NFxB in the nucleus and thus are useful in the treatment of a variety of diseases including but not limited to rheumatoid arthritis, rheumatoid spondylitis. osteo-arthritis, other arthritic conditions, septic shock, septis, endotoxic shock, graft versus host disease.
wasting, Crohn's disease, ulcerative colitis, multiple sclerosis, systemic lupus en~thrematosis, ENL
in leprosy, HIV, AIDS, and opportunistic infections in AIDS.
TNFa and NFxB levels are influenced by a reciprocal feedback loop. As noted above, the compounds of the present invention affect the levels of both TNFa and NFxB. It is not known at this time, however, how the compounds of the present invention regulate the levels of TNFa, NFxB, or both.
Many cellular functions can be mediated by levels of adenosine 3',5'-cyclic monophosphate(cAMP). Such cellular functions can contribute to inflammatory conditions and diseases including asthma, inflammation, and other conditions (Lowe and Cheng, Drugs of the Future) 17(9), 799-807, 1992). It has been shown that the elevation of cAMP in inflammatory leukocytes inhibits their activation and the subsequent release of inflammatory mediators.
Increased levels of CAMP also leads to the relaxation of airway smooth muscle.
BACKGROUND OF THE INVENTION
The present invention relates to a method of reducing levels of TNFa and inhibiting phosphodiesterase in a mammal and to compounds and compositions useful therein.
TNFa, or tumor necrosis factor a, is a cytokine which is released primarily by mononuclear phagocytes in response to various immunostimulators. When administered to animals or humans it causes inflammation, fever, cardiovascular effects, hemorrhage, coagulation and acute phase responses similar to those seen during acute infections and shock states.
Excessive or unregulated TNFa production has been implicated in a number of disease conditions. These include endotoxemia and/or toxic shock syndrome {Tracey et al., Nature 330, 662-664 (1987) and Hinshaw et al., Circ. Shock 30, 279-292 (1990)}; cachexia {Dezube et al., Lancet) 335(8690), 662 (1990)}; and Adult Respiratory Distress Syndrome where TNFa concentration in excess of 12,000 pg/milliliter have been detected in pulmonary aspirates from ARDS patients {Millar et al., Lancet 2(8665), 712-714 (1989)}. Systemic infusion of recombinant TNFa also resulted in changes typically seen in ARDS {Ferrai-Baliviera et al., Arch. Surg. 124(12), 1400-1405(1989)}.
TNFa appears to be involved in bone resorption diseases, including arthritis where it has been determined that when activated, leukocytes will produce a bone-resorbing activity, and data suggest that TNFa contributes to this activity. {Bertolini et al., Nature 319, 516-518 (1986) and Johnson et al., Endocrinology 124(3), 1424-1427 (1989).} It has been determined that TNFa stimulates bone resorption and inhibits bone formation in vitro and in vivo through stimulation of osteoclast formation and activation combined with inhibition of osteoblast function. Although TNFa may be involved in many bone resorption diseases, including arthritis, the most compelling link with disease is the association between production of TNFa by tumor or host tissues and malignancy associated hypercalcemia {Calci. Tissue Int. (US) 46(Suppl.), S3-10 (1990)}. In Graft versus Host Reaction, increased serum TNFa levels have been associated with major complication following acute allogenic bone marrow transplants {Holler et al., Blood, 75(4), 1011-1016 (1990)}.
Cerebral malaria is a lethal hyperacute neurological syndrome associated with high blood levels of TNFa and the most severe complication occurring in malaria patients.
Levels of serum TNFa correlated directly with the severity of disease and the prognosis in patients with acute malaria attacks {Grau et al., N Engl. J. Med. 320(24), 1586-1591 (1989)}.
TNFa also plays a role in the area of chronic pulmonary inflammatory diseases.
The deposition of silica particles leads to silicosis, a disease of progressive respiratory failure caused by a fibrotic reaction. Antibody to TNFa completely blocked the silica-induced lung fibrosis in mice {Pignet et al., Nature, 344:245-247 (1990)}. High levels of TNFa production (in the serum and in isolated macrophages) have been demonstrated in animal models of silica and asbestos induced fibrosis {Bissonnette et al., Inflammation 13(3), 329-339 (1989)}. Alveolar macrophages from pulmonary sarcoidosis patients have also been found to spontaneously release massive quantities of TNFa as compared with macrophages from normal donors {Baughman et al., J. Lab.
Clin. Med.
115(1). 36-42 (1990)}.
TNFa is also implicated in the inflammatory response which follows reperfusion, called reperfusion injury, and is a major cause of tissue damage after loss of blood flow {Vedder et al., PNAS 87, 2643-2646 (1990)}. TNFa also alters the properties of endothelial cells and has various pro-coagulant activities, such as producing an increase in tissue factor pro-coagulant activity and suppression of the anticoagulant protein C pathway as well as down-regulating the expression of thrombomodulin {Sherry et al., J. Cell Biol. 107, 1269-1277 (1988)}. TNFa has pro-inflammatory activities which together with its early production (during the initial stage of an inflammatory event) make it a likely mediator of tissue injury in several important disorders including but not limited to, myocardial infarction, stroke and circulatory shock. Of specific importance may be TNFa-induced expression of adhesion molecules, such as intercellular adhesion molecule (ICAM) or endothelial leukocyte adhesion molecule (ELAM) on endothelial cel Is { Munro et al. , Am.
J. Path. 13~( 1 ), 121-132 (1989)}.
Moreover. it now is known that TNFa is a potent activator of retrovirus replication including activation of HIV-1. {Duh et al., Proc. Nat. Acad Sci. 86, 5974-X978 (1989);
Poll et al., Proc: Nat.
Acad. Sci. 87, 782-785 (1990); Monto et al., Blood 79, 2670 (1990); Clouse et al., J. Immunol. 142.
431-43 8 ( 1989): Poll et al., AIDS Res. Hum. Retrovirus, 191-197 ( 1992) } .
AIDS results from the infection of T lymphocytes with Human Immunodeficiency Virus (HIV). At least three types or strains of HIV have been identified, i.e., HIV-1, HIV-2 and HIV-3. As a consequence of HIV
infection, T-cell mediated immunity is impaired and infected individuals manifest severe opportunistic infections and/or unusual neoplasms. HIV entry into the T
lymphocyte requires T lym-phocy~te activation. Other viruses, such as HIV-1, HIV-2 infect T lymphocytes after T cell activation and such virus protein expression and/or replication is mediated or maintained by such T cell activa-tion. Once an activated T lymphocyte is infected with HIV, the T lymphocyte must continue to be maintained in an activated state to permit HIV gene expression and/or HIV
replication. Cytokines, specifically TNFa, are implicated in activated T-cell mediated HIV protein expression and/or virus replication by playing a role in maintaining T lymphocyte activation.
Therefore, interference with cyokine activity such as by prevention or inhibition of cyokine production.
notably TNFa, in an HIV-infected individual aids in limiting the maintenance of T lymphocyte caused by HIV infection.
Monocytes, macrophages, and related cells, such as kupffer and glial cells, have also been implicated in maintenance of the HIV infection. These cells, like T cells, are targets for viral replication and the level of viral replication is dependent upon the activation state of the cells.
{Rosenberg et al., The Immunopathogenesis ofHIVlnfection, Advances in Immunology, 57 (1989)}.
Cytokines, such as TNFa, have been shown to activate HIV replication in monocytes andlor macrophages {Poli et al. Proc. Natl. Acad. Sci., 87, 782-784 (1990)}, therefore, prevention or inhibition of cytokine production or activity aids in limiting HIV progression as stated above for T
cells. Additional studies have identified TNFa as a common factor in the activation of HIV in vitro and has provided a clear mechanism of action via a nuclear regulatory protein found in the cytoplasm of cells (Osborn, et al. , PAPAS 86, 2336-2340). This evidence suggests that a reduction of TNFa synthesis may have an antiviral effect in HIV infections, by reducing the transcription and thus virus production.
HIV viral replication of latent HIV in T cell and macrophage lines can be induced by TNFa {Folks et al., PNAS 86, 2365-2368 (1989)}. A molecular mechanism for the virus inducing activity is suggested by TNFa's ability to activate a gene regulatory protein (NFxB) found in the cytoplasm of cells, which promotes HIV replication through binding to a viral regulatory gene sequence (LTR) {Osborn et al., PNAS 86, 2336-2340 (1989)}. TNFa in AIDS and cancer associated cachexia is sug-Bested by elevated semen TNFa and high levels of spontaneous TNFa production in peripheral blood monocytes from patients { Wright et al. J. Immunol. 141(1), 99-104 (1988)}.
{Eur J. Gastroen Hepat, 6_(9), 821-829 (1994)}. {J. Exp. Med., 1121-1227 (1988)}.
TNFa has been implicated in various roles with other viral infections, such as the cytomegalia virus (CMV), influenza virus, adenovirus, and the herpes family of viruses for similar reasons as those noted.
Preventing or inhibiting the production or action of TNFa is, therefore.
predicted to be a potent therapeutic strategy for many inflammatory, infectious, immunological or malignant diseases.
These include but are not restricted to septic shock. sepsis, endotoxic shock, hemodynamic shock and sepsis syndrome, post ischemic reperfusion injury, malaria, mycobacterial infection. meningitis, psoriasis, congestive heart failure, fibrotic disease, cachexia, graft rejection, cancer, autoimmune disease, opportunistic infections in AIDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, other arthritic conditions, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, systemic lupus erythrematosis, ENL in leprosy, asthma, radiation damage, and hyperoxic alveolar injury. Efforts directed to the suppression of the effects of TNFa have ranged from the utilization of steroids such as dexamethasone and prednisolone to the use of both polyclonal and monoclonal antibodies {Beutler et al., Science 234, 470-474 (1985); WO 92/11383}.
(Clinical.and Experimental Rheumatology 1993., ~ (Suppl. 8), 5173-5170. (PNAS
1992, 89, 9784-88). (Annals of the Rheumatic Diseases 1990, 4~, 480-486).
The nuclear factor xB (NFxB) is a pleiotropic transcriptional activator (Lenardo, et al. Cell 1989, 58, 227-29). NFxB has been implicated as a transcriptional activator in a variety of disease and inflammatory states and is thought to regulate cytokine levels including but nit limited to TNFa and also to be an activator of HIV transcription (Dbaibo, et al. J. Biol.
Chem. 1993, 17762-66; Duh et al. Proc. Natl. Acad. Sci. 1989, 86, 5974-78; Bachelerie et al. Nature 1991, 350, 709-1?; Boswas et al. J.. Acquired Immune Deficiency Syndrome 1993, 6, 778-786; Suzuki et al.
Biochcm. And Biophys. Res. Comm. 1993, 193, 277-83; Suzuki et al. Biochem. And Biophys. Res Comm. 1992, 189. 1709-1 ~; Suzuki et al. Biochem. Mol. Bio. Int. 1993, 3 I (4), 693-700;
Shakhov et al. 1990, 171, 35-47; and Staal et al. Proc. Natl. Acad. Sci. USA 1990, 87, 9943-47). Thus, inhibition of NFxB
binding can regulate transcription of cytokine genes) and through this modulation and other mechanisms be useful in the inhibition of a multitude of disease states. The compounds claimed in this patent can inhibit the action of NFxB in the nucleus and thus are useful in the treatment of a variety of diseases including but not limited to rheumatoid arthritis, rheumatoid spondylitis. osteo-arthritis, other arthritic conditions, septic shock, septis, endotoxic shock, graft versus host disease.
wasting, Crohn's disease, ulcerative colitis, multiple sclerosis, systemic lupus en~thrematosis, ENL
in leprosy, HIV, AIDS, and opportunistic infections in AIDS.
TNFa and NFxB levels are influenced by a reciprocal feedback loop. As noted above, the compounds of the present invention affect the levels of both TNFa and NFxB. It is not known at this time, however, how the compounds of the present invention regulate the levels of TNFa, NFxB, or both.
Many cellular functions can be mediated by levels of adenosine 3',5'-cyclic monophosphate(cAMP). Such cellular functions can contribute to inflammatory conditions and diseases including asthma, inflammation, and other conditions (Lowe and Cheng, Drugs of the Future) 17(9), 799-807, 1992). It has been shown that the elevation of cAMP in inflammatory leukocytes inhibits their activation and the subsequent release of inflammatory mediators.
Increased levels of CAMP also leads to the relaxation of airway smooth muscle.
The primary cellular mechanism for the inactivation of cAMP is the breakdown of cAMP
by a family of isoenzymes referred to as cyclic nucleotide phosphodiesterases (PDE) (Beavo and Reitsnyder, Trends in Pharm., 11, 150-155) 1990). There are seven known members of the family of PDEs. It is recognized, for example, that the inhibition of PDE type IV is particularly effective in both the inhibition of inflammatory mediator release and the relaxation of airway smooth muscle (Verghese, et al. , Journal of Pharmacology and Experimental Therapeutics, 272(3), 1313-1320, 1995). Thus, compounds that inhibit PDE IV specifically, would exhibit the desirable inhibition of inflammation and relaxation of airway smooth muscle with a minimum of unwanted side effects, such as cardio-vascular or anti-platelet effects.
Currently used PDE IV
inhibitors lack the selective action at acceptable therapeutic doses.
The compounds of the present invention are useful in the inhibition of phosphodiesterases, particularly PDE III and PDE IV, and in the treatment of disease states mediated thereby.
Detailed Description The present invention is based on the discovery that a class of non-polypeptide imides/amides more fully described herein appear to inhibit the acxion of TNFa.
The present invention pertains to compounds of the formula:
~C
R3 /N H-( C Hz ) n O-Rz ~t R
in which R' is (i) straight, branched, or cyclic, substituted or unsubstituted alkyl of 1 to 12 carbon atoms, (ii) phenyl or phenyl substituted with one or more substituents.
where each substituent is selected independently of the other from nitro, cyano, trifluoromethyl.
by a family of isoenzymes referred to as cyclic nucleotide phosphodiesterases (PDE) (Beavo and Reitsnyder, Trends in Pharm., 11, 150-155) 1990). There are seven known members of the family of PDEs. It is recognized, for example, that the inhibition of PDE type IV is particularly effective in both the inhibition of inflammatory mediator release and the relaxation of airway smooth muscle (Verghese, et al. , Journal of Pharmacology and Experimental Therapeutics, 272(3), 1313-1320, 1995). Thus, compounds that inhibit PDE IV specifically, would exhibit the desirable inhibition of inflammation and relaxation of airway smooth muscle with a minimum of unwanted side effects, such as cardio-vascular or anti-platelet effects.
Currently used PDE IV
inhibitors lack the selective action at acceptable therapeutic doses.
The compounds of the present invention are useful in the inhibition of phosphodiesterases, particularly PDE III and PDE IV, and in the treatment of disease states mediated thereby.
Detailed Description The present invention is based on the discovery that a class of non-polypeptide imides/amides more fully described herein appear to inhibit the acxion of TNFa.
The present invention pertains to compounds of the formula:
~C
R3 /N H-( C Hz ) n O-Rz ~t R
in which R' is (i) straight, branched, or cyclic, substituted or unsubstituted alkyl of 1 to 12 carbon atoms, (ii) phenyl or phenyl substituted with one or more substituents.
where each substituent is selected independently of the other from nitro, cyano, trifluoromethyl.
carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino,acylamino, alkyl(dialkyl)amino, alkyl of 1 to 10 carbon atoms, cycloalkyl of 3 to carbon atoms, bicycloalkyl of 5 to 12 carbon atoms, alkoxy of 1 to 10 carbon atoms, cycloalkoxy of 3 to 10 carbon atoms, bicycloalkoxy of 5 to 12 carbon atoms, or halo;
R= is -H. alkyl of I to 8 carbon atoms, benzy, pyridylmethyl, or alkoxymethyl;
R' is i) ethylene, ii) vinylene, iii) a branched alkylene of 3 to 10 carbon atoms, iv) a branched alkenylene of 3 to 10 carbon atoms, v) cycloalkylene of 4 to 9 carbon atoms unsubstituted or substituted with 1 or more substituents each selected independently from vitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy. carboxy, 10 hydroxy, amino, substituted amino alkyl of 1 to 6 carbon atoms. substituted amino acyl of 1 to 6 carbon atoms) alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 12 carbon atoms, or halo, vi) cycloalkenylene of 4 to 9 carbon atoms unsubstituted or substituted with I or more substituents each selected independently from vitro, cyano, trifluoromethyh carbethoxy, carbomethoxy. carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino alkyl of 1 to 6 carbon atoms, substituted amino acyl of I to 6 carbon atoms, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 12 carbon atoms, or halo, vii) o-phenylene unsubstituted or substituted with 1 or more substituents each selected independently from vitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl. carbamoyl, acetoxy, carboxy, hydroxy, amino. substituted amino alkyl of 1 to 6 carbon atoms, substituted amino acyl of 1 to 6 carbon atoms, alkyl of 1 to 10 carbon atoms.
alkoxy of 1 to 12 carbon atoms, or halo, viii) napthyl, or ix) pyridyl;
R4 is -CX-, -CH,- or -CH,CX-;
XisOorS;
and, n is 0,1,2, or 3.
A first preferred subclass of Formula II pertains to compounds in which R' is o-phenylene where:
R' is 3,4-diethoxyphenyl or 3-ethoxy-4-methoxyphenyl and R4 is -CO-, -CH,- or -CHzCO-.
Typical compounds of this invention include 3-phthalimido-3-(3',4'-dimethoxyphenyl)propan-1-ol;
2-phthalimido-2-(3',4'-dimethoxyphenyl)ethanol;
3-phthaIimido-3-(3'.4'-diethoxyphenyl)propan-1-ol;
3-phthalimido-3-(3',4'-dimethoxyphenyl)-I -methoxvpropane;
2-phthalimido-2-(3',4'-dimethoxyphenyl)-1-methoxyethane;
3-phthalimido-3-(3',4'-diethoxyphenyl)-1-methoxypropane;
3-phthalimido-3-(3',4'-dimethoxyphenyl)-1-ethoxypropane;
3-phthalimido-3-(3',4'-dimethoxyphenyl)-I-(3-pyridylmethoxy)propane;
3-phthalimido-3-(3',4'-diethoxyphenyl)-1-(3-pyridylmethoxyl)propane;
3-phthalimido-3-napthylpropan-1-ol;
3-phthalimido-3-(3',4'-diethylphenyl)propan-I-ol;
3-phthalimido-3-(3',4'-dipropylphenyl)propan-I -ol;
3-phthalimido-3-(3',4'-diethylphenyl)-1-methoxypropane;
3-phthalimido-3-(3',4'-diethoxyphenyl)-1-ethoxypropane;
3-phthalimido-3-cyclohexyl-1-methoxypropane;
3-phthalimido-3-(3',4'-diethylcyclohexyl)-I-methoxypropane;
3-(I'-oxoisoindolinyl)-3-(3',4'-dimethoxyphenyl)propan-1-ol;
2-( I'-oxoisoindolinyl)-2-(3',4'-dimethoxyphenyl)ethanol;
3-( I'-oxoisoindolinyl)-3-(3',4'-diethoxyphenyl)propan-1-ol;
-25 3-(1'-oxoisoindolinyl-3-(3',4'-dimethoxyphenyl)-1-methoxypropane;
2-(1'-oxoisoindolinyl)-2-(3',4'-dimethoxyphenyl)-I-methoxyethane;
_g_ WO 98/247b3 PCT/US97/22369 ~-(I'oxoisoindolinyl)-3-(3',4'-diethoxyphenyl)-1-methoxypropane;
3-( I'-oxoisoindolinyl)-3-(3',4'-dimethoxyphenyl)-I-ethoxypropane;
3-( 1'-oxoisoindolinyl)-3-(3',4'-dimethoxyphenyl)-I-(3-pyridylmethoxy)propane;
3-( 1'-oxoisoindolinyl)-3-(3',4'-diethoxyphenyl)-I -(3-pyridylmethoxyl)propane;
3-(1'-oxoisoindolinyl)-3-napthylpropan-I-ol;
3-( I'-oxoisoindolinyl)-3-(3',4'-diethylphenyl)propan-I-ol;
3-( 1'-oxoisoindolinyl)-3-(3',4'-dipropylphenyl)propan-1-ol;
3-( I'-oxoisoindolinyl)-3-(3',4'-diethylphenyl)-I -methoxypropane;
3-( 1'-oxoisoindoliny l)-3-(3',4'-diethoxyphenyl)- I -ethoxypropane.
3-phthalimido-3-(3'-ethoxv-4'-methoxyphenyl)propan-1-of 3-phthalimido-3-(3'-ethoxv-4'-methoxyphenyl)-I-methoxypropane 3-phthalimido-3-(3'-propoxy-4'-methoxyphenyl)propan-1-of 3-phthalimido-3-(3'-propoxy-4'-methoxyphenyl)-1-methoxypropanc 3-phthalimido-3-(3'-cyclopentoxy-4'-methoxyphenyl )propan-1-of 3-phthalimido-3-(3'-cyclopentoxy-4'-methoxyphenyl)-1-methoxypropanc 3-phthalimido-3-(3'-isopropoxy-4'-methoxyphenyl)propan-1-of 3-phthalimido-3-(3'-isopropoxy-4'-methoxyphenyl)-1-methoxypropane 3-phthalimido-3-(3'-ethoxy-4'-ethylphenyl)propan-1-of 3-phthalimido-3-(3'-ethoxv-4'-ethylphenyl)-1-meth~mprc~pam 3-( 1'-oxoisoindolinyl)-3-(3'-ethoxy-4'-methoxyphcw I ~- ; -mr;tww pr«pan:
3-( 1'-oxoisoindolinyl)-3-(3'-propoxy-4'-methoxypheny I ~propan- I -o I
3-( 1'-oxoisoindol inyl)-3-(3'-propoxy-4'-methoxyphenyl)- I -methoxypropane 3-( I'-oxoisoindolinyl)-3-(3'-cyclopentoxy-4'-methoxyphenyl)propan-I-of 3-( 1'-oxoisoindolinyl)-3-(3'-cyclopentoxy-4'-methoxyphenyl}-I-methoxypropane 3-( 1'-oxoisoindolinyl)-3-(3'-isopropoxy-4'-methoxyphenyl)propan-1-of 3-( I'-oxoisoindolinyl)-3-(3'-isopropoxy-4'-methoxyphenyl)-I-methoxypropane 3-( I'-oxoisoindolinyl)-3-(3'-ethoxy-4'-ethylphenyl)propan-I-of 3-( 1'-oxoisoindolinyl)-3-(3'-ethoxy-4'-ethylphenyl)-1-methoxypropane 3-(3-aminophthalimido)-3-(3'-ethoxy-4'-methoxyphenyl)-1-methoxypropane 3-(3-aminophthalimido)-3-(3'-propoxy-4'-methoxyphenyl)propan-1-of 3-(3-aminophthalimido)-3-(3'-propoxy-4'-methoxyphenyl)-1-methoxypropane 3-(3-aminophthalimido)-3-(3'-cyclopentoxy-4'-methoxyphenyl)propan-1-of 3-(3-aminophthalimido)-3-(3'-cyclopentoxy-4'-methoxyphenyl)-1-methoxypropane 3-(3-aminophthalimido)-3-(3'-isopropoxy-4'-methoxyphenyl)propan-1-of 3-(3-aminophthalimido)-3-(3'-isopropoxy-4'-methoxyphenyl)-1-methoxypropane 3-(3-aminophthalimido)-3-(3'-ethoxy-4'-ethylphenyl)propan-1-of 3-(3-aminophthalimido)-3-(3'-ethoxy-4'-ethylphenyl)-1-methoxypropane 3-(3-hydroxyphthalimido)-3-(3'-ethoxy-4'-methoxyphenyl)-1-methoxypropane 3-(3-hydroxyphthalimido)-3-(3'-propoxy-4'-methoxyphenyl)propan-1-of 3-(3-hydroxyphthalimido)-3-(3'-propoxy-4'-methoxyphenyl)-1-methoxypropane 3-(3-hydroxyphthalimido)-3-(3'-cyclopentoxy-4'-methoxyphenyl)propan-1-of 3-(3-hydroxyphthalimido)-3-(3'-cyclopentoxy-4'-methoxyphenyl)-1-methoxypropane 3-(3-hydroxyphthalimido)-3-(3'-isopropoxy-4'-methoxyphenyl)propan-1-of 3-(3-hydroxyphthalimido)-3-(3'-isopropoxy-4'-methoxyphenyl)-1-methoxypropane 3-(3-hydroxyphthalimido)-3-(3'-ethoxy-4'-ethylphenyl)propan-1-of 3-(3-hydroxyphthalimido)-3-(3'-ethoxy-4'-ethylphenyl)-1-methoxypropane 3-homophthalimido-3-(3'-ethoxy-4'-methoxyphenyl)-1-methoxypropane 3-homophthalimido-3-(3'-propoxy-4'-methoxyphenyl)propan-1-of 3-homophthalimido-3-(3'-propoxy-4'-methoxyphenyl)-1-methoxypropane 3-homophthalimido-3-(3'-cyciopentoxy-4'-methoxyphenyl)propan-1-of 3-homophthalimido-3-(3'-cyclopentoxy-4'-methoxyphenyl)-1-methoxypropane 3-homophthaiimido-3-(3'-isopropoxy-4'-methoxyphenyl)propan-1-of 3-homophthalimido-3-{3'-isopropoxy-4'-methoxyphenyl)-1-methoxypropane 3-homophthalimido-3-(3'-ethoxy-4'-ethylphenyl)propan-1-of WO 9$!24763 PCT/US97/22369 3-homophthalimido-.i-(3'-ethoxy-4'-ethylphenyl)-1-methoxypropane 3-(4-aminophthalimido)-3-( 3'-ethoxy-4'-methoxypheny 1 )-1-methoxypropane 3-(4-aminophthalimido)-3-(3'-propoxy-4'-methoxyphenyl)propan-1-of 3-(4-aminophthalimido)-3-(3'-propoxv-4'-methoxyphenyl)-1-methoxypropane 3-(4-aminophthalimido)-3-(3'-cyclopentoxy-4'-methoxyphenyl)propan-1-of 3-(-i-aminophthalimido)-3-(3'-cyclopentoxy-4'-methoxyphenyl)-1-methoxypropane -3-(4-aminophthalimido)-3-(3'-isopropoxy-4'-methoxyphenyl)propan-1-of 3-(4-aminophthalimido)-3-(3'-isopropoxy-4'-methoxyphenyl)-1-methoxypropane 3-(4-aminophthalimido)-3-(3'-ethoxy-4'-ethylphenyl)propan-1-of 3-(-1-aminophthalimido)-3-(3'-ethoay-d'-ethylphenyl)-1-methoxypropane The temp alkyl as used herein denotes a univalent saturated branched or straieht hydrocarbon chain. Unless otherwise stated. such chains can contain from 1 to 18 carbon atoms. Representative of such alkyl groups are methyl. ethyl. propyl, isopropyl. butyl, isobutyl.
sec-bum!. tent-buy!, penwl.
isopenwl. neopentyl, tent-pentyl. hexyl. isohexyh heptyl, octyl. nonyl. decyl.
undecyl. dodecvl.
1~ tridecyl. tetradecyl. pentadecyl. hexadecyl. heptadecyh octadecyl, and the like. ~i'hen qualified by "lower". the alkyl group will contain from 1 to 6 carbon atoms. The same carbon content applies to the parent term "alkane" and to derivative terms such as "alkoxv".
The compounds can be used, under the supewision of qualified professionals, to inhibit the undesirable effects of TlrFa. The compounds can be administered orally, rectallv, or parenterallv.
?0 alone or in combination with other therapeutic agents including antibiotics. steroids. etc.. to a mammal in need of treatment. Oral dosage forms include tablets, capsules, dragees) and similar shaped. compressed pharmaceutical forms. Isotonic saline solutions containing ?0-100 milligrams/milliliter can be used for parenteral administration which includes intramuscular.
intrathecal, intravenous and infra-arterial routes of administration. Rectal administration can be effected through the use of suppositories formulated from conventional carriers such as cocoa butter.
Dosage regimens must be titrated to the particular indication, the age.
weight. and general physical condition of the patient, and the response desired but generally doses will be from about 1 to about 500 milligrams/day as needed in single or multiple daily administration. In general, an initial treatment regimen can be copied from that known to be effective in interfering with TNFa activity for other TNFa mediated disease states by the compounds of the present invention. Treated individuals will be regularly checked for T cell numbers and T4/T8 ratios and/or measures of viremia such as levels of reverse transcriptase or viral proteins, and/or for progression of cytokine-mediated disease associated problems such as cachexia or muscle degeneration. If no effect is found following the normal treatment regimen, then the amount of cytokine activity interfering agent administered is increased, e.g., by fifty percent a week.
The compounds of the present invention also can be used topically in the treatment or prophylaxis of topical disease states mediated or exacerbated by excessive TNFa production.
respectively, such as viral infections, such as those caused by the herpes viruses, or viral conjunctivitis) etc.
The compounds also can be used in the veterinary treatment of mammals other than humans in need of prevention or inhibition of TNFa production. TNFa mediated diseases for treatment.
therapeutically or prophylactically, in animals include disease states such as those noted above. but in particular viral infections. Examples include feline immunodeficiency virus. equine infectious anaemia virus, caprine arthritis virus, visna virus, and mac~ii virus. as w.li as other lentiviruses Certain of these compounds possess eentrr~ c~t vh~talm an;'. car exist as optical i,c~mrr~
Both the racemates of these isomers and the indimdua! m~m:w th:msclyes. as well as dias:err«mr,-.
when there are two chiral centers, are within the scope of the present invention. The racerratr~ can be used as such or can be separated into their individual isomers mechanically as by chromatography using a chiral absorbant. Alternatively, the individual isomers can be prepared in chiral form or separated chemically from a mixture by forming salts with a chiral acid, such as the individual enantiomers of Z O-camphorsulfonic acid, camphoric acid, alpha-bromocamphoric acid.
methoxyacetic acid, tartaric acid, diacetyltartaric acid, malic acid, pyrrolidone-5-carboxylic acid, and the like, and then freeing one or both of the resolved bases, optionally repeating the process, so as to obtain either or both substantially free of the other; i. e., in a form having an optical purity of >95%.
Prevention or inhibition of production of TNFa by these compounds can be conveniently assayed using anti-TNFa antibodies. For example, plates (Nunc lmmunoplates, Roskilde, DK) are treated with 5 pg/milliliter of purified rabbit anti-TNFa antibodies at 4°C for 12 to 14 hours. The plates then are blocked for 2 hours at 25°C with PBS/0.0~% Tween containing milligrams/milliliter BSA. After washing, 100 gL of unknowns as well as controls are applied and the plates incubated at 4°C for 12 to 14 hours. The plates are washed and assayed with a conjugate of peroxidase (horseradish) and mouse anti-1'NFa monoclonal antibodies, and the color developed with o-phenylenediamine in phosphate-citrate buffer containing 0.012% hydrogen peroxide and read at 492 nm.
The compounds can be prepared using methods v~~hich are known in general for the preparation of imides. A preferred general reaction scheme includes the reaction of a substituted amine with an appropriate anhydride. Other synthetic methods known in the art may be used, for example. phthalimido compounds are made by reacting the substituted amine with either phthalic anhydride, N-carbethoxyphthalimide, or phthalic dicarboxaldehyde as illustrated by the formulas:
O O
II RN H., A P~C~O + Ph\C NR
Ip O
O O
P~C~NCOzEt + RN HZ ----~ Ph'C j R
I o Ph'C H + RNH, ---~ ptr~O NR
I_H Ci O
q q R3'Ci0 + RN HZ ~ R3\CiN R
D) R' q R' R3~~ NQ + CH ORS --~ C\
2)n R3~ N--\R4~ X ~Ra~ ~CHz)nOR=
RN H
F ~ O + 2 --~ PtrC~NR
CHZ ~ CH_-O O
The following examples will serve to further typify the nature of this invention but should not be construed as a limitation in the scope thereof; which scope is defined solely by the appended claims.
3-Amino-3-(3',4'-dimethoxyphenyf)propionic acid A stirred suspension of 3,4-dimethoxybenzaldehyde (131 grams, 788 mmol) and ammonium acetate (121.5 grams, 1576 mmol) in ethanol (9~%, 400 mL) was heated to 45-50 °C resulting in an orange solution. To this solution was added malonic acid (82.0 grams, 788 mmol) and the solution was refluxed overnight. A white solid precipitated on heating, the slurry was allowed to cool to room temperature and was filtered. The solid was washed with ethanol, air dried.
and dried in vacuo (60°C, < 1 mm) to afford 3-amino-3-(3',4'-dimethoxyphenyl)propionic acid as a white solid, (100.14 grams, 56% yield), no further purification was carried out: mp 208.0-210.0 °C; 'H NMR
(D~O/NaOD/TSP) 8 7.08-6.91 (m, 3H), 4.22 (t, J= 7 Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 2.55 (dd, J= 2, 7Hz, 2H); "C NMR (D~O/NaOD/TSP) 8 182.9, 150.8. 149.8, 140.7, 121.6, 114.6. 112.8, 58.6, 55.4, 49.8.
Methyl 3-amino-3-(3',4'-dimethoxyphenyl)propionate.
To a stirred suspension of 3-amino-3-(3', 4'-dimethoxyphenyl)propionic acid (70.1 grams, 312 mmol) in methanol (400 mL) at 0 °C, was added acetyl chloride (47.6 mL, 667 mmol) dropwise.
After an additional 1 ~ minutes, the ice-water bath was removed. The resulting clear solution was stirred at room temperature for 2 hours. The system was opened and the solvent was blown off with N, overnight. To the solid was added methanol (50 mL) and ether (300 mL). The resulting suspension was stirred at room temperature for I hour. The suspension was filtered and the solid . 10 was washed with ether (100 mL). The solid was dissolved in a mixture of sodium carbonate (200 mL, sat), water (300 mL), and methylene chloride (2~0 mL). The organic layer was separated. The aqueous layer was extracted with methylene chloride (3 X 2~0 mL). The combined organic layers were dried over magnesium sulfate. Removal of solvent gave methyl 3-amino-3-{3'.4'-dimethoxyphenvl)propionate as an oil (60.2 grams. 81% yield): 'H NMR (CDCI_) b 1.77 (s, 2H, 1~ NH,), 2.65 (d, J= 7 Hz, 2H, CH_), 3.68 (s. 3H, CH;), 3.87 (s, 3H, CH;).
3.89 (s. 3H. CH;). 4.39 (t, J = Hz. 1 H. Cl~. 6.81-6.93 (m. 3H, Ar); 'rC NIvIR (CDCI;) 8 44.00. ~ 1.48, X2.18. ».72. ».76.
109.20, 111.02, 118.02. 137.21. 148.1 l, 1-18.93, 172.34; Anal. Calcd for C,=H,,NO, 0.1 H,O C, X9.19; H, 7.19; N, x.81. Found: C, 59.38; H, 7.09; N, 5.91.
20 3-Amino-3-(3',4'-dimethoxyphenyl)-propan-1-ol.
A solution of 3-amino-3-(3',4'-dimethoxyphenyl)-propionate (4.12 grams. 17.2 mmol) in methanol (~0 milliliters) was slowly added to stirred sodium borohydride (6.51 grams, 17.2 mmol). After the initial effervescence had ceased the mixture was refluxed for 1 hour. Reaction progress was monitored by TLC (20% ethyl acetate/hexane, uv) and was complete after 1 hour.
The reaction mixture was allowed to cool and then 20 milliliters of water was added. The methanol was removed in vacuo resulting in the formation of a gum which was extracted into methylene chloride (3 X 20 milliliters). The combined extracts were dried over magnesium sulfate and concentrated to afford an oil which was refrigerated. A waxy solid formed which was dried in vacuo (60 oC , < 1 ~) to afford 3.30 g (86%) of the product as a white solid. 'H NMR (CDCI3) S 6.91-6.78(m , 3H), 4.15-4.04(m , 1H), 3.89(s , 3H), 3.88{s , 3H), 3.84-3.71(s , 2H), 3.91-2.45(broad m , 1H), 1.95-1.78(m , 2H).
3-Amino-3-(3', 4'-dimet6oxypheayl)-1-propanol To a stirred solid of sodium borohydride (94.18 grams, 2.49 mol) at 0 °C. was added methanol (50 mL). To this mixture at 0 °C was added a solution of methyl 3-amino-3-{3', 4'-dimethoxyphenyl)propionate (S9.S grams, 249 mmol) in methanol (9S0 mL) over 1 hour. The mixture was stirred in that ice-water bath until the temperature of the reaction mixture staved at 3S
1S °C or lower for 30 minutes. (Caution: If the ice-water bath was removed too early, a highly exothermic reaction may occur.) The water bath was then removed and the solution was refluxed for 16 hours. The solution was allowed to cool to room temperature. To the solution was added water {300 mL), followed by methylene chloride (2S0 mL) at 0 °C. The resulting suspension was filtered. Half of the filtrate was removed in vacuo. The resulting solution was dissolved in methylene chloride (S00 mL) and water (300 mL). The organic layer was separated. The aqueous layer was extracted with methylene chloride (3 X 500 mL). The combined organic layers were washed with brine ( 100 mL), and dried over magnesium sulfate. Removal of solvent gave an oil.
The resulting oil was dried in vacuo to afford 3-amino-3-(3',4'-dimethoxvphenyl)-1-propanol as a white solid (42.15 grams, 80% yield): mp 63.5-65.5 °C;'H NMR (CDC1,) 8 6.91-6.78(m , 3H), 4.15-4.04(m , 1H), 3.89(s , 3H), 3.88(s , 3H), 3.84-3.71(s , 2H), 2.91-2.4~(m , 1H), 1.95-1.78(m , 2H); Anal Calcd for C"H"N03: C, 62.54; H, 8.11; N, 6.63. Found: C, 62.01; H, 7.80; N, 6.49.
3-Phthalimido-3-(3',4'-dimethoxyphenyl)propan-1-ol.
A mixture of 3-amino-3-(3',4'-dimethoxyphenyl)-propan-1-of (1.11 grams, ~
mmol) and phthalic anhydride (0.74 grams, 5 mmol) were melted together and stirred for 5 minutes.
After cooling, a green/yellow glassy semi solid formed which was stirred in ether to afford 1.62g (95°io) of crude product as a white solid. The crude product was purified by flash chromatography (silica gcl. 40%
ethyl acetate/methylene chloride) to afford 1.25 grams (73%) of product as a white solid. 'H NMR
(CDCI;) 5 7.8~-7.63 (m , 4 H), 7.18-7.07 (m , 2 H), 6.86-6.76 (m , 1 H), x.62-5.49(m , 1 1-i), 3.88 (s , 3 H), 3.85 (s , 3 H), 3.79-3.63 (m , 2 H), 2.89-2.71 (m . 1 H), 2.64-2.47 {m , I H), 1.87-1.73 (br m , 1 H). '' C NMR (CDCI;) 8 168.x, 148.8, 148.6, 133.9, 131.8, 131.7, 123.2, 1 ?0.7, I 11.6, 1 I 0.8, 59.8, 5~.0, 55.8, 51.4, 33.9. Anal. Calcd. for C,9H,9N05. Theoretical : C
,66.85 ; 1-I , 5.61 : N , 4.10.
Found : C,66.70 ; H , 5.60 ; N , 4.06. HPLC 100%.
13 3-Amino-3-(3'-ethoxy-4'-methoxyphenyl)propionic acid A stirred mixture of 3-ethoxy-4-methoxybenzaldehyde ( 119.5 grams, 664 mmol ) and ammonium acetate ( 148.3 grams, 1.92 mol) in ethanol (300 mL, 95%) was heated at 45 °C. To the mixture was added malonic acid (69 grams, 664 mmol), followed by ethanol (100 mL, 95%).
The mixture was refluxed for 18 hours. The mixture was cooled to room temperature and was stirred for 2 hours. The suspension was filtered and the solid was washed with cold ethanol (5 x ~0 mL) to give 3-amino-3-(3'-ethoxy-4'-methoxyphenyl)propionic acid as a white solid, which was dried in a vacuum oven overnight, (94.7 grams, 60% yield): mp, 224.0-225.5 °C;'H NMR
(D,O/NaOD) 8 1.41 (t, J= 7 Hz, 3H, CH3}, 2.52-2.56 {m, 2H, CHz), 3.83 (s, 3H, CH;), 4.14 (q, J= 7 Hz, 2H, CH,), 4.19 (t, J=
WO 98/24763 PCT/US97/223b9 7 Hz, 1 H, NCH), 6.98-7.04 (m, 3H, Ar); "C NMR (D~O/NaOD) 8 16.75, 49.81, 55.45, X8.46) 67.63, 114.17, 114.71, 121.76, 140.69, 149.91, 150.09, 182.97; Anal. Calcd for C,ZH"NO,: C, 60.24; H.
7.16; N, 5.85. Found: C, 60.21; H, 7.12; N, 5.88.
Methyl3-amino-3-(3'-ethoxy-4'-methoxyphenyl)propionate.
To a stirred suspension of 3-amino-3-(3'-ethoxy-4'-methoxyphenyl)propionic acid (89.47 grams.
374.4 mmol) in methanol (500 mL) at 0 °C, was added acetyl chloride (~4 mL, 757 mmol) dropwise.
After 1 ~ minutes, the ice-water bath w.~as removed. The resulting clear solution was stirred at room temperature for 2 hours. The system was opened and the solvent was blown off with :~i~ overnight.
To the solid was added methanol (50 mL) and ether {300 mL). The resulting suspension was stirred at room temperature for 1 hour. The suspension was filtered and the solid was washed with ether ( 100 mL). The solid was dissolved in a mixture of sat aqueous sodium carbonate (200 mL), water (200 mL), and methylene chloride (2~0 mL). The organic layer was separated.
The aqueous layer was extracted with methylene chloride (3 X 2~0 mL). The combined organic layers were dried over magnesium sulfate. Removal of solvent gave methyl 3-amino-3-(3'-cyclopentoxy-4'-methoxyphenyl)propionate as an oil (80.84 grams, 85% yield): 'H~NMR (CDCI;) 8 1.46 (t, J= 7 Hz, 3H, CH;), 1.75 (s, 2H, NHz), 2.64 (d, J= 7 Hz, 2H, CH,), 3.68 (s, 3H, CH3), 3.86 (s, 3H, CH;), 4.10 (q, J= 7 Hz, 2H, CHZ), 5.36 (t, J= 7 Hz, 1H, NCH), 6.80-6.91 (m, 3H, Ar);
''C NMR (CDCI;) b 14.74, 44.09, 51.55, 52.23, 55.91, 64.23, 110.77, 111.39, 118.07, 137.21, 148.31, 148.49, 172.44.
3-Amino-3-(3'-ethoxy-4'-methoxyphenyl)-1-propanol To a stirred solid of sodium borohydride (121 grams, 3.19 mol) at 0 °C, was added methanol {50 mL). To this mixture at 0 °C was added a solution of methyl 3-amino-3-(3 ~-ethoxy-4'-methoxyphenyl)propionate (80.84 grams, 319.5 mmol) in methanol (1500 mL) over 1 hour. The mixture was stirred in that ice-water bath until the temperature of the reaction mixture stayed at 35 °C or lower for 30 minutes. (Early removal of the ice bath may result in a highly exothermic reaction). The water bath was then removed and the solution was refluxed for 16 hours. The solution was allowed to cool to room temperature. To the solution was added water (300 mL).
followed by methylene chloride (250 mL) at 0 °C. The resulting suspension was filtered. Half of the filtrate was removed in vacuo. The resulting solution was dissolved in methylene chloride (500 mL) and water (300 mL). The organic layer was separated. The aqueous layer was extracted with methylene chloride (3 X S00 mL). The combined organic layers were washed with brine (100 mL), and dried over magnesium sulfate. Removal of solvent gave an oil. The resulting oil was dried in vacuo to afford 3-amino-3-{3'-ethoxy-4'-methoxyphenyl)-1-propanol as a white solid (~3 grams.
74% yield): 'H NMR (CDCl3) 8 1.47 (t, J= 6.8 Hz, 3H, CH;), 1.84-1.90 (m, 2H, CH ). 2.58 (br s.
3H) NH=, OH). 3.78 (t, J= 5.5 Hz, 2H, OCH~), 3.86 {s, 3H, CH;), 4.04-4.15 (m, 3H, CH , NCH).
6.84 (s. 3H, Ar); ''C NMR (CDCI;) 8 14.74, 39.78, 55.84, 5.91, 61.86, 64.28, I10.5~, 111.47, 1~ 117.8, 138.82. 148.27, 148.32; Anal. Calcd for C,,H,9N03: C, 63.98; H, 8.50; N, 6.22. Found: C.
63.73; H, 8.44: N, 6.14.
3-(3'-Ethoxy-4'-methoxyphenyl)-3-phthalimido-I-propanol A mixture of 3-amino-3-(3'-ethoxy-4'-methoxyphenyl)-1-propanol (8.4 grams, 37.3 mmol) and sodium carbonate (3.95 grams, 37.3 mmol) in acetonitrile and water (40 mL
each) was stirred at room temperature for 15 minutes. To the solution was added N-carbethoxyphthalimide (8.18 grams, 37.3 mmol) as solid. After 20 minutes, the acetonitrile was removed under vacuum. The aqueous solution was extracted with methylene chloride (3 X 50 mL). The combined organic layers were washed with HCl (40 mL, 1N), and dried over magnesium sulfate. Removal of solvent gave a green ?5 oil. Ether (2~ mL) was added to the oil, then hexane (2 mL) was added. A
suspension formed and the solid m~as filtered to give 3-(3'-ethoxy-4'-methoxyphenyl)-3-phthalimido-1-propanol as a white solid, 1 g. The mother liquor was purified by chromatography (silica gel 500grams, 10, 15, 20%
EtOAc/CH~CI,) to give 3-(3'-ethoxy-4'-methoxyphenyl)-3-phthalimido-1-propanol as a solid, 2.54 g. Total yield was 3.54 g (27% yield): mp, 112.0-114.0 °C; 'H NMR
(CDCI;) 8 I .45 (t, J= 7 Hz, 3H, CH3), 1.59-1.65 (br s, 1H, OH), 2.49-2.59 (m, IH, CHH), 2.71-2.83 (m, IH, CHH)) 3.66-3.69 (m, 2H, OCH:), 3.84 (s, 3H, CH3), 4.10 (q, J= 7 Hz, 2H, MeCI-~ ), 5.53 (dd. J
= 6.5. 9.5 fIz, 1 H, NCH), 6.81 (d, J = 8.2 Hz, 1 H, Ar), 7.09-7.27 (m, 2H, Ar), 7.66-7.72 (m, 2H, Ar), 7.76-7.82 (m, 2H, Ar}; '3C NMR (CDCI,) 8 14.72, 33.86, 51.46, 55.88, 59.84, 64.34, 111.16, 113.05. 120.68, 123.20, 131.64, 131.86, 133.94, 148.17, 148.97, 168.49; Anal Calcd for C2°H,,NOS: C. 67.59: I-I, 5.96; N.
3.94. Found: C, 65.40; H, 5.8 i ; N, 3.84.
3-Amino-3-(3-cyclopenh~loxy-4-methoxyphenyl)propionic acid A stirred mixture of 3-cyclopentyloxy-4-methoxybenzaldehyde (54.9 grams) 249 mmol) and ammonium acetate (58.2 grams, 748 mmol) in ethanol (200 mL, 95%) was heated to 45 °C. To the yellowish suspension, was added malonic acid (25.9 grams, 249 mmol) as a solid. The mixture was refluxed for lb h. The mixture was cooled to room temperature. The suspension was filtered and the solid was washed with cold ethanol (200 mL) until the color was removed.
The ~~hite solid was dried in a vacuum oven (45 °C, 1 torr) to afford 3-amino-3-(3'-cyclopentoxy-4'-methoxyphenyl)propionic acid as white solid (41.97 grams, 61% yield): mp, 234.0-235.0 °C; 'H
NMR (CDC13) b 1.62-1.98 (m, 8H, CSHB), 2.53 (d, J= 7 Hz, 2H, CI~), 3.80 (s, 3H, CI~), 4.21 (t, J= 7 Hz, 1 H, OCH), 4.84-4.86 (m, 1 H, NCH), 6.96-7.03 (m, 3H, Ar); "C NMR
(CDC1;) b 26.33, 34.97, 49.78, 55.32, 58.48, 83.99, 114.99, I 16.04, 121.63, 140.63, 149.12, 150.75, I82.87; Anal Calcd for C,SHZ,NOa: C, 64.50; H, 7.58; N, 5.01. Found: C, 64.54; H, 7.68; N, 4.93.
Methyl 3-amino-3-(3'-cyclopentoxy-4'-methoxyphenyl)propionate To a stirred suspension of 3-amino-3-(3'-cyclopentyloxy-4'-methoxyphenyl)propionic acid (30 grams, 279 mmol) in methanol ( 1 ~ 0 mL) at 0 °C, was added acetyl chloride ( 15.2 mL, 212 mmol) dropwise. After 15 minutes, the ice-water bath was removed. The resulting clear solution was stirred at room temperature for 2h. The system was opened and the solvent was blown off with N
overnight. To the solid was added methanol (50 mL) and ether (300 mL). The resulting suspension was stirred at room temperature for 1 h. The suspension was filtered and the solid was washed with ether ( 100 mL,). The solid was dissolved in a mixture of aqueous sodium carbonate (200 mL, sat), water (200 mL), and methylene chloride (250 mL). The organic layer was separated. The aqueous layer was extracted with methylene chloride (3 X 250 mL). The combined organic la~~ers were dried over magnesium sulfate. Removal of solvent gave methyl 3-amino-3-(3'-cyclopentoxy-4'-methoxyphenyl)propionate as an oil (28.41 grams, 90% yield): 'H NMR (CDCI;) 8 1.~6-1.97 (m, IOH, NH,, CSHB). 2.62 (d, J= 7 Hz, 2H, CH,), 3.67 (s, 3H, CH;), 3.81 (s, 3H, CH;), 4.34 (t, J= 6.8 Hz. 1 H, CH), 4.74-4.79 (dd, J = 5, 8.5 Hz, 1 H, NCH), 6.78-6.90 (m, 3H, Ar);
''C NMR (CDC1;) 8 23.97, 32.76, 44.17, 51.58, 52.25, 56.07, 80.37, 111.96, 113.08, 119.08, 137.2, 147.72, 149.27, 172.49.
3-Amino-3-(3'-cyclopenh~ioxy-4'-methoxyphenyl)-1-propanol To a stirred solid of sodium borohydride (37 grams, 978 mmol) at 0 °C, was added methanol (50 mL). To this mixture at 0 °C was added a solution of methyl 3-amino-3-(3'-cyclopentyloxy-4'-methoxyphenyl)propionate {27 grams, 92.2 mmol) in methanol (500 mL) over 1 h.
The mixture was stirred in that ice-water bath until the temperature of the reaction mixture stayed at 35 °C or lower for 30 minutes. (Caution: If the ice-water bath was removed too early, a highly exothermic reaction may occur.) The water bath was then removed and the solution was refluxed for 16h. The solution was allowed to cool to room temperature. To the solution was added water ( I
25 mL), followed by methylene chloride (250 mL) at 0 °C. The resulting suspension was filtered. ~Ialf of the filtrate was removed in vacuo. The resulting solution was dissolved in methylene chloride (250 mL) and water (200 mL). The organic layer was separated. The aqueous layer was extracted with methylene chloride (3 X 250 mL). The combined organic layers were washed with brine ( 100 mL), and dried over magnesium sulfate. Removal of solvent gave an oil. The resulting oil was dried in vacuo to afford 3-amino-3-(3'-cyclopentyloxy-4'-methoxyphenyl)-1-propanol as a white solid (22.3 grams, 91% yield): mp, 216.0-217.5 °C; 'H NMR (CDCI;) 8 1.52-1.68 (m, 2H, CHZ), 1.76-1.91 (m, 8H, C5H8), 2.92 (brs, 3H, NHz, OH), 3.76 (t, J= 5.5 Hz. 2H, CH=}. 3.82 (s, 3H, CH3), 4.06 (t, J= Hz, I H, OCH), 4.76-4.79 (m, 1 H, NCH), 6.82-6.84 (m, 3H, Ar); '= C NMR (CDCI;) b 23.96, 32.75, 39.91, 55.59, 56.10, 61.62. 80.46, 112.11, 112.99, 117.75, 138.65. 147.74, 149.12; Anal Calcd for C,SH,;N03 0.05 CH,C1~: C, 67.05; H, 8.64, N, 5.20. Found: C. 67.02; H, 8.41;
N, 5.08.
3-(3'-Cyclopentyloxy-4'-methoxyphenyl)-3-phthalimido-1-propanol A mixture of 3-amino-3-(3'-cyclopentyloxy-4'methoxyphenyl}-1-propanol (4.31 grams, 16.24 mmol) and phthalic anhydride (2.41 grams. 16.27 mmol) was melted vvth a heat gun for 6 minutes.
The mixture was allowed to cool to room temperature. Chromatography (silica gel 100 grams. 1:5 EtOAc:CHzCl2) gave 3-(3'-cyclopentyloxy-4'-methoxyphenyl)-3-phthalimido-1-propanol as solid.
(4.97 grams, 77% yield): mp, 59.0-61.0 °C; 'H NMR (CDCl3) S 1.56-I .98 (m, 9H, OH, C ~ll~l, 2.48-2.59 (m, 1H, CHIC, 2.71-2.83 (m, 1H, CHH), 3.b6-3.74 (m, 2H, OCH,), 3.80 (s, 3H, CH;), 4.74 4.80 (m, 1 H, CH), 5.51 (dd, J = 6.5, 9.4 Hz, I H, NCH), 6.78 (d, J = 8.3 Hz, 1 H, Ar), 7.05-7.09 (m, 1 H, Ar), 7.16-7.17 (m, 1 H, Ar), 7.64-7.70 (m, 2H, Ar), 7.75-7.81 (m, 2H, Ar); "C NMR (CDCI;) 8 24.02, 32.71, 38.84, 51.44, 55.94, 59.75, 80.35, I I I .58, I 15.06, 120.54, 123.12, 131.60, 131.80, 133.86, 147.48, 149.55, 168.43; Anal Calcd for C~;Hz5N05: C, 69.86; H, 6.37;
N, 3.54. Found: C, 69.51; H, 6.41; N, 3.54.
3-(3'-Ethoxy-4'-methoxyphenyl)-3-(3"-nitro-phthalimido)-1-propanol A mixture of 3-amino-3-(3'-ethoxy-4'methoxyphenyl)-1-propanol (4.0 grams, 17.8 mmol) and 3-nitrophthalic anhydride (3.44 grams, 19.8 mmol) was melted with a heat gun for 6 minutes. The mixture was allowed to cool to room temperature. Chromatography (silica gel 80 grams, 1:5 EtOAc:
CH,CI_) gave 3-(3'-ethoxy-4'-methoxy)phenyl-3-(3"-nitro-phthalimido)-1-propanol as a yellow solid, (3.67 grams, 52% yield): mp, 143.0-145.0 °C; 'H NMR (CDCI;) b 1.47 (t, J= 7Hz, 3H, CHI.
I .48-I .52 (brs, 1 H. OH), 2.51-2.62 (m, 1 H, CHH), 2.72-2.84 (m, 1 H, CHH), 3.69-3.73 (m, 2H, CH,), 3.85 (s, 3H, CH;), 4.12 (q, J= 7 Hz, 2H, CH,), 5.56 (dd, J= 6.~, 9 Hz, 1H, NCN), 6.82 (d, J= 8 Hz, 1 H, Ar), 7. I I -7.15 (m, 2H, Ar), 7.85-7.91 (m, I H, Ar), 8.06-8.09 (m, 2H, Ar); ''C NMR (CDCI;) ~ 14.71, 33.51, 52.61, 55.91, 59.87, 64.43, 111.26, 113.08, 120.91, 123.52.
126.91. 128.43, 130.82, 133.97. 13.21, 145.13, 148.27, 149.25, 163.02, 165.97; Anal Calcd for C:°H,°N,O,: C. 60.00; H, 5.03; N, 7.00. Found: C, 59.83; H, 4.97; N, 6.86.
3-(3"-Amino-phthalimido)-3-(3'-ethoxy-4'-methoxyphenyl)-I-propanol A mixture of 3-(3'-ethoxy-4'-methoxyphenyl)-3-(3"-nitro-phthalimido)-1-propanol (600 mg, 1.~
mmol) and Pd/C (100 mg, 10%) in ethyl acetate (40 mL) was shaken under hydrogen (~0 psi) for 16h. The mixture was filtered through a pad of celite. Removal of solvent and chromatography (silica gel 80 grams, 1:3 EtOAc:CH,CI,) gave 3-(3"-amino-phthalimido)-3-(3'-ethoxy-4'-methoxyphenyl)-1-propanol as a yellow solid, (495 mg, 89% yield): mp, 81.0-83.0 °C; 'H NMR
(CDCI;) 8 1.45 (t, J= 6.8 Hz, 3H, CH3), 1.80 (brs., IH, OH), 2.45-2.52 (m, 1H, CHH), 2.71-2.80 (m, 1H, CHH), 3.66-3.75 (m, 2H, OCH,), 3.84 (s, 3H, CH,), 4.09 (q, J= 6.8 Hz, 2H, CH,), 5.23 (br s, 2H, I~TH,), 5.47 (dd, J= 6.4, 9.8 Hz, 1H, CH)) 6.78-6.83 (m, 2H, Ar), 7.07-7.13 (m, 3H, Ar), 7.33-7.39 (m, 1 H, Ar); ''C NMR (CDC13) 8 14.72, 33.92. 50.79, 55.87, 59.76, 64.34, 111.03. 111.14.
112.01, 113 .07, I 20.52, 121.60, 131.94, 132.49, 13 5.09, 145.24, 148. I 1, 148.84, 168.76, 170.31;
Anal Calcd for C,oH~,N~05: C, 64.85; H, 5.99; N, 7.56. Found: C, 64.44; H, 6.I4; N, 6.88.
3-(3'-Ethoxy-4'-methoxyphenyl)-3-(3',4',5',6'-tetrahydrophthalimidoyl)-1-propanol A mixture of 3-amino-3-(3'-ethoxy-4'-methoxyphenyl)-1-propanol (4.0 grams, 17.7~mmo1) and 3.4,5,6-tetrahydrophthalic anhydride (2.80 grams, 18.4 mmol) was melted with a heat gun for 6 minutes. The mixture was allowed to cool to room temperature. Chromatography (silica eel 150 grams, 1:3 EtOAc:CH,CI,) gave 3-(3'-ethoxy-4'-methoxyphenyl)-3-(3',4',5',6'tetrahydrophthalimidoyl)-1-propanol as an oil, (4.96 grams. 75%
yield): 'I-I NMR
(CDCI;) 8 1.45 (t, J= 6.8 Hz, 3H, CHI, 1.70-1.80 (m. 4H, CH= CH~1. 1.91 (brs, 1H, OtT), 2.27-'?.32 (m, 4H, CH,. CH,), 2.41-2.58 (m, 1 H, CHI7), 2.61-2.68 (m, I H. CI-ill). 3.59-3.65 (m, 2I-I. CN 1. 3. f~-i (s. 3H, CH;), 4.09 (q, J= 6.9 Hz, 2H, CH,), 5.26 (dd..l = 6.6, 9.5 Hz. 1 H, NCH), 6.79 (d. .l = 8 Hz.
1 H, Ar), 7.00-7.09 (m, 2H, Ar); '3C NMR (CDCl3) 8 14.64, 19.83, 21.19, 34.10, 50.90, 55.79. 59.6.
64.24, 111.04, 112.86, 120.41, 132.11, 141.28, 148.01. 148.7 3. 171.19: Anal Calcd for C,;,I-I:.NO.
C, 66.84; H. 7.01; N, 3.90. Found: C, 66.89; 1-I. 6.R4: l~. ~ 7 EXAMPL.F 17 3-(3',4'-Dimethoxyphenyl)-3-(1'-oxoisoindolinyl)-1-propanol To a stirred suspension of 3-(3',4'-dimethoxyphenyl)-3-(1'-oxoisoindolinyl)propionic acid (3.7.1 grams, 10.96 mmol) in THF (60 mL) at -10-15 °C (ice-salt bath), was added borane in THF ( 1 1 mL.
1 M, 11 mmol). The suspension was allowed to warm to room temperature slowly overnight. To the resulting clear solution was added water (20 mL), followed by potassium carbonate (6 g). The organic layer was separated. The aqueous layer was extracted with methylene chloride (2 X 50 mL).
The combined organic layers were washed with sodium carbonate (20 mL, sat), brine (20 mL), and dried over magnesium sulfate. Removal of solvent and chromatography (silica gel, 100 grams, 1:2, I:1 EtOAc/CH,C12) gave 3-(3',4'-dimethoxyphenyl}-3-(1'-oxoisoindolinyl)-I-propanol as an oil, (2.52 grams, 70%). Ether (6 mL) and 2 drops of methanol were added to the oil.. Hexane was added until the solution was turned cloudy. The mixture was stirred for 30 minutes to give a white solid and the solid was filtered: mp, 101.5-103.0 °C; 'H NMR (CDC13) b 1.99-2.36 (m, 3H, CH,, OH), 3.49-3 . 80 (m, 2H, OCHz), 3.86 (s, 3 H, CHI, 3.89 (s, 3 H, CH ~, 3 .91 (d, J
= 17.2 Hz, 1 H, CHl~, 4.19 (d, J = 17.2 Hz, 1 H, CHH), 5.75 (dd, J = 4, 11.5 Hz, 1 H, NCH), 6.86-7.00 (m, 3 H, Ar), 7.27-7.56 (m, 3H, Ar), 7.86-7.89 (m, 1 H, Ar); "C NMR (CDC13) 8 33.87, 46.22, 50.61, 55.91, 56.01, 58.56, 111.04, 111.73. 119.66, 122.81, 123.89, 128.64, 131.33, 131.66, 132.09, 141.35, 148.81, 148.24.
I 69.46; Anal Calcd for C,9Hz,N0,: C, 69.71; H, 6.47; N, 4.28. Found: C, 69.51; H. 6.27; N, 4.12.
3-{3',4'-Dimethoxyphenyl)-1-methoxy-3-phthalimidopropane To a solution of 3-(3',4'-dimethoxyphenyl)-3-phthalimido-1-propanol (1.02 grams, 2.99 mmol) and IS methyl iodide (0.37 mL, 5.94 mmol) in THF (10 mL) at room temperature, was added NaH (358 mg, 60%. 8.96 mmol). The mixture was stirred at room temperature for 46 minutes.
and then was retluxed for 2h. To the cooled mixture was added a few drops of NH4C1, then HC1 (1N, 26 mL).
The organic layer was separated. The aqueous layer was extracted with ethyl acetate (3 X 26 mL).
The combined organic layers were washed with brine (26 mL), and dried over magnesium sulfate.
Removal of solvent and chromatography (silica gel 100 grams, 1:5 EtOAc:hexane) gave 3-(3',4'-dimethoxyphenyl)-1-methoxy-3-phthalimidopropane as a white solid, (750 mg, 71%
yield): mp, 91.5-92.5 °C; 'H NMR (CDCI,) 8 2.50-2.59 (m, 1H, CHH), 2.70-2.86 (m, IH, CHH), 3.27 (s, 3H, CH;), 3.39 (t, J= 6 Hzr2H, CHI, 3.85 (s, 3H, CHI, 3.88 (s, 3H, CH), 5.49 (dd, J= 6.8, 9.2 Hz, 1H, NCH), 6.81 (d, J = 8 Hz, 1 H, Ar), 7.11-7. I 5 (m, 2H, Ar), 7.67-7.72 (m, 2H, Ar), 7.77-7.83 (m, 2H, Ar); "C NMR (CDC13) 8 31.29, 51.93, 55.80, 58.69, 69.64, 110.84, 115.56, 120.62, 123.12, 131.90, WO 98/24763 PCTlUS97/22369 1332.03, 133.84, 148.58, 148.81, 168.38; Anal Calcd for Cz°H,,NOS: C, 67.59; H, 5.96: N, 3.94.
Found: C, 67.54; H, 5.97; N, 3.84.
3-{3'-Ethoxy-4'-methoxyphenyl)-1-methoxy-3-phthalimidopropane.
To a stirred mixture of sodium hydride (110 mg, 60%, 2.75 mmol) in THF (8 mL) at room temperature, was added iodomethane (0.54 grams, 3.78 mmol) followed by 3-(3'-ethoxy-4'-methoxyphenyl)-3-phthalimido-1-propanol (850 mg, 2.39 mmol). The mixture was stirred at room temperature for 15h. To the mixture was added NHaCI (20 mL, sat). The organic layer was separated. The aqueous layer was extracted with methylene chloride (2 X 50 mL). The combined organic layers were washed with brine {50 mL) and dried over magnesium sulfate. Removal of solvent and chromatography (silica gel 200 grams, 1:12 EtOAc:CH=C1,) gave 3-(3'-ethoxy-4'-methoxyphenyl)-I-methoxy-3-phthalimidopropane as an oil (360 mg. 41% yield).
The resulting oil solidified after standing at room temperature over weekend: mp, 67.5-70.0 °C; 'H NMR (CDCI;) 8 I .45 (t, J = 7 Hz, 3 H, CH3), 2.50-2.60 (m, 1 H, CHH), 2.71-2.85 (m, 1 H, CHH), 3.26 (s, 3 H, CH;), i 5 3.3 9 (t, J = 6 Hz, 2H, CH,), 3 .84 (s, 3 H, CH3), 4.10 (q, J = 7Hz, 2H, CH,), 5.47 {dd. J = 7, 9.3 Hz, 1 H, NCH), 6.81 (d, J = Hz, 1 H, Ar), 7.09-7.16 (m, 2H, Ar), 7.66-7.69 (m, 2H, Ar), 7.76-7.82 (m, 2H, Ar). '3C NMR (CDCI;) 8 (APT) 14.67 (CI-~ ), 31.23 (CI-h ), 51.89 (CI-~ ), 58.63 (CH), 64.25 (CH,), 69.62 (CH,), 111.13 (CH), 112.98 (CH), 120.58 (CH), 123.06 (CH), 131.87 (C), 131.92 (C), 133.78 (CH), 148.09 (C), 148.84 (C), 168.33 (C); Anal Calcd for C,,H,3N05 0.05 H=O: C, 67:66;
H, 6.23; N, 3.75. Found: C, 67.91; H, 6.00; N, 3.71.
3-(3'-Cyclopentyloxy-4'-methoxyphenyl)-1-methoxy-3-phthalimidopropane.
To a solution of 3-(3'-cyclopentyloxy-4'-methoxyphenyl)-3-phthalimido-1-propanol (786 mg, 1.99 mmol) and methyl iodide (0.25 mL, 4.0 mmol) in THF (10 mL) at room temperature, was added NaH { I 60 mg, 60%, 4.0 mmol). The mixture was stirred at room temperature for I h, and then was refluxed for 35 minutes. The mixture was allowed to cool to room temperature.
To the resulting mixture was added a few drops ofNH4Cl, then HCl (1N, 25 mL). The organic layer was separated.
The aqueous layer was extracted with ethyl acetate (3 X 30 mL). The combined organic layers were washed with brine (25 mL), and dried over Na,S04. Removal of solvent and chromatography (silica gel 100 grams, 1:5 EtOAc:hexane) gave 3-(3'-cyclopentyloxy-4'-methoxyphenyl)-1-methoxy-3-phthalimidopropane as an oil, (510 mg, 63% yield). The oil solidified upon standing at room temperature to give a white solid: mp, 77.5-80.0 °C; 'H NMR (CDCI,) 8 1.58-1.96 (m, 8H, CSHB), 2.45-2.55 (m, 1 H, CHI, 2.70-2.85 (m, I H, CHH), 3.26 (s, 3H, CH3), 3.39 (t, J= 6 Hz, 2H, CH,), 3.81 (s, 3H, CH,), 4.78-4.80 (m, I H, OCH), 5.46 (dd, J= 7, 9.3 Hz, 1 H, NCH), 6.79 (d, J = 8.3 Hz, 1 H. Ar), 7.06-7.10 (m, 1 H, Ar), 7.17-7.26 (m, 1 H, Ar), 7.67-7.69 (m, 2H, Ar), 7.78-7.82 (m, 2 H, Ar); ''C NMR (CDC13) 8 24.08, 31.30, 32.76, 51.94, 56.00, 58.71, 69.71, 80.37, 111.63, 115.09.
120.53, 123.12. 131.92, 131.96, 133.81, 147.53, 149.55, 169.37; Anal Calcd for C,,H_,NOS: C.
70.40; H, 6.65; N, 3.42. Found: C, 70.32; H, 6.61; N, 3.31.
I-Ethoxy-3-(3'-ethoxy-4'-methoxyphenyi)-3-phthalimidopropane.
To a stirred solution of 3-(3'-ethoxy-4'-methoxypheny!)-3-phthalimido-1-propanol (1 gram, 2.82 mmol), ethyl bromide (0.42 mL, 5.63 mmol), and tetrabutyl ammonium iodide (200 mg, 0.54 mmol) in THF ( 10 mL) at room temperature, was added NaH (270 mg, 60%, 6.75 mmol).
The mixture was stirred at roam temperature for 45 minutes, and then was heated to reflux for 4h. To the mixture was added a few drops ofNH~CI, then HCl (1N, 25 mL). The organic layer was separated. The aqueous layer was extracted with ethyl acetate (3 X 25 mL). The combined organic layers were washed with brine (25 mL), and dried over magnesium sulfate. Removal of solvent and chromatography (silica gel 100 grams, 1:5 EtOAc:hexane) gave 1-ethoxy-3-(3'-ethoxy-4'-methoxyphenyl)-phthalimidopropane as an oil, (800 mg, 74% yield): 'H NMR (CDCI3) 8 1.06 (t, J= 7Hz, 3H, CH;), 1.46 (t, J= 7 Hz, 3H, CH;), 2.46-2.58 (m, 1H, CHH), 2.75-2.95 (m, IH, CHH), 3.37 (q, J= 7 Hz, 2H, CHz),.3.44 (q, J= 7 Hz, 2H, CH,), 3.85 (s, 3H, CH,), 4.12 (q, J= 7 Hz, 2H, CH,), 5.49 (dd, J
= 6.4, 9.5 Hz, I H, NCH), 6.81 (d, J = 8.2 Hz, 1 H, Ar), 7.10-7.48 (m, 2H, Ar), 7.68-7.72 (m, 2H, Ar), 7.77-7.83 (m, 2H, Ar); '3C NMR (CDCI;) 8 14.73, 14.98, 31.31, 52.24, 55.89, 64.30. 66.33, 67.73, I I 1. I 1 ( 1 I 2.99, 120.61, 123. I 1, 132.00, 132.09, 13 3.80, 148.11, 148.84. 168.44; Anal Calcd for Cz2H,~N05: C, 68.91; H, 6.57; N, 3.65. Found: C, 68.77; H, 6.47; N, 3.57.
1-Benzyloxy-3-(3'-ethoxy-4'-methoxyphenyl)-3-phthalimidopropane To a stirred solution of 3-(3'-ethoxy-4'-methoxyphenyl)-3-phthalimido-1-propanol (680 mg, 1.92 mmol), benzyl bromide (0.46 ml,, 3.86 mmol), and tetrabutyl ammonium iodide (80 mg. 0.21 mmol) in THF (20 mL,) at room temperature, was added NaH (240 mg, 60%, 6.0 mmol).
The mixture was stirred at room temperature for 15h. To the mixture was added a few drops of NH~CI. then HCI ( 1 N, 25 mL). The organic layer was separated. The aqueous layer was extracted with ethyl acetate (3 X
25 mL). The combined organic layers were washed with brine (25 mL), and dried over magnesium sulfate. Removal of solvent and chromatography (silica gel 100 grams, 1:5 EtOAc:hexane) gave 1-benzyloxy-3-(3'-ethoxy-4'-methoxyphenyl)-3-phthalimidopropane as an oil, (510 mg. 60% yield):
'H NMR (CDCI,) 8 1.46 (t, J= 6.9 Hz, 3H, CH ), 2.51-2.59 (m, TH, CHI-, 2.86-2.96 (m, 1H, CHH), 3.51 (t, J = 5.5 Hz, CH~), 3.85 (s, 3 H, CH3 ), 4.10 (q, J = 7 Hz, CHZ
), 4.43 (s, 2H, PhCl~ ).
5.54 (dd, J = 6.5, 9.5 Hz, 1 H, NCH), 6. 80 (d, J = 8 Hz, 1 H, Ar), 7.09-7.27 (m, 7H, Ar), 7.65-7.79 (m. 4H, Ar); ''C NMR (CDC13) b 14.73, 31.37, 52.12, 55.88, 64.29, 67.31, 73.10, 1 I 1.11, 1 i 2.95, 120.59, 123.09, 127.42, 127.62, 128.22, 131.92, 132.09, 133.77, 138.09, 148.12, 148.84, 168.42;
Anal Calcd for C,,H,,NOS: C, 72.79; H, 6.11; N, 3.14. Found: C, 72.66; H, 6.32; N, 3.16.
WO 98/24763 PCTlUS97/22369 3-(3',4'-Dimethoxyphenyl)-I-ethoxy-3-(1'-oxoisoindolinyl)propane To a stirred solution of 3-(3',4'-dimethoxyphenyl)-3-(1'-oxoisoindolinyl)-I-propanol (500 mg, 1.53 mmol), ethyl bromide (0.27 mL, 3.62 mmol) and tetrabutyl ammonium iodide (60 mg, 0.16 mmol) in THF ( 10 mL) at room temperature, was added NaH ( 160 mg, 60%, 4.0 mmol).
The mixture was stirred at room temperature for 4h. To the mixture was added NH4C1 (20 mL, sat). The organic layer was separated. The aqueous layer was extracted with methylene chloride (2 X 2~ mL). The combined organic layer was dried over magnesium sulfate. Removal of solvent and chromatography (silica gel 120 grams, 1:6 EtOAc:CH,CI,) gave 3-(3',4'-dimethoxyphenyl)-1-ethoxy-3-(1'-o~oisoindolinyl)propane as an oil, (420 mg, 77% yield): 'H NMR (CDCI;) 8 1.09 (t, ,I= 7Hz, 3H, CH;), 2.35-2.4~ (m, 2H, CH,), 3.35-3.58 (m, 4H, CH,OCH,), 3.84 (s, 3H, CH;), 3.86 (s, 3H, CH;).
4.00 (d, J = 16.8 Hz, 1 H, NCHH), 4.3 5 (d, J = 16.8 Hz, 1 H, NCHH), 5.66 (dd, J = 6, 9.3 Hz, 1 H) NCH). 6.82-6.98 (m, 3H, Ar), 7.35-7.53 (m) 3H, Ar), 7.84-7.88 (m, 1 H, Ar);
''C NMR (CDCI,) 8 1 x.02. 31.62, 4.82, ~ 1.~ 1. 5.82, X5.90, 66.39, 67.86, I 10.90, 111.27, 119.15, 122.68, 3 23.71.
127.86) 131.16, 1-32.28, 132.73, 141.28, 148.49, 149.08, 168.38; Anal Calcd for C,,H,SNO, 0.3 HBO:
C. 69.90; H, 7.1 ~; N, 3.88. Found: C, 69.69; H, 6.80; N, 3.73.
Tablets, each containing ~0 milligrams of active ingredient, can be prepared in the following manner:
Constituents (for 1000 tablets) active ingredient 50.0 g lactose 50.7 g wheat starch 7.5 g polyethylene glycol 6000 5.0 g talc 5.0 g magnesium stearate 1.8 g demineralized water q.s.
The solid ingredients are first forced through a sieve of 0.6 mm mesh width.
The active ingredient, the lactose, the talc, the magnesium stearate and half of the starch are then mixed. The other half of the starch is suspended in 40 milliliters of water and this suspension is added to a boiling solution of the polyethylene glycol in 100 milliliters of water. The resulting paste is added to the pulverulent substances and the mixture is granulated, if necessary with the addition of water. The granulate is dried overnight at 35 °C, forced through a sieve of 1.2 mm mesh width and compressed-to form tablets of approximately 6 mm diameter which are concave on both sides.
EXAMPLE 2~
Tablets, each containing 100 milligrams of active ingredient. can be prepared in the following manner:
Constituents (for 1000 tablets) active ingredient 100.0 g lactose 100.0 g wheat starch 47.0 L
magnesium stearate : 0 g All the solid ingredients are first forced throuLh ~ sieve ~,1 U t~ mm mesh width. The acuvc ingredient, the lactose, the magnesium stearate and half of the starch then are mixed. The other half of the starch is suspended in 40 milliliters of water and this suspension is added to 100 milliliters of boiling water. The resulting paste is added to the pulverulent substances and the mixture is granulated, if necessary with the addition of water. The granulate is dried overnight at 35 °C, forced through a sieve of 1.2 mm mesh width and compressed to form tablets of approximately 6 mm diameter which are concave on both sides.
Tablets for chewing, each containing 75 milligrams of active ingredient, can be prepared in the following manner:
Composition (for 1000 tablets) active ingredient 75.0 g mannitol 230.0 g lactose 1 X0.0 g talc 21.0 g glycine 12.5 g stearic acid 10.0 g saccharin l,j g 5% gelatin solution q,s.
All the solid ingredients are first forced through a sieve of 0.25 mm mesh width. The mannitol and the lactose are mixed, granulated with the addition of gelatin solution, forced through a sieve of 2 mm mesh width, dried at 50 °C and again forced through a sieve of 1.7 mm mesh width.
The active ingredient, the glycine and the saccharin are carefully mixed, the mannitol. the lactose granulate, the stearic acid and the talc are added and the whole is mixed thoroughly and compressed to form tablets of approximately 10 mm diameter which are concave on both sides and have a breaking groove on the upper side.
Tablets, each containing 10 milligrams of active ingredient, can be prepared in the following manner:
Coml osition (for 1000 tablets) active ingredient 10.0 g lactose 328.5 g corn starch 17,j g polyethylene glycol 6000 5.0 g talc 25.0 g magnesium stearate 4.0 g demineralized water q.s.
The solid ingredients are first forced throueh a sieve of 0.6 mm mesh width.
Then the active ingredient, lactose. talc, magnesium stearate and half of the starch are intimately mixed. The other half of the starch is suspended in 65 milliliters of water and this suspension is added to a boiling solution of the polyethylene glycol in 260 milliliters of water. The resulting paste is added to the pulverulent substances, and the whole is mixed and granulated, if necessary with the addition of water. The granulate is dried overnight at 35 °C, forced through a sieve of 1.2 mm mesh width and compressed to form tablets of approximately 10 mm diameter which are concave on both sides and have a breaking notch on the upper side.
Gelatin dry-filled capsules, each containing 100 milligrams of active ingredient. can be prepared in the following manner:
Composition (for 1000 capsules) active ingredient 100.0 g microcrystalline cellulose 30.0 g sodium lauryl sulphate 2.0 g magnesium stearate 8.0 g The sodium lauryl sulphate is sieved into the active ingredient through a sieve of 0.2 mm mesh width and the two components are intimately mixed for 10 minutes. The microcrystalline cellulose is then added through a sieve of 0.9 mm mesh width and the whole is again intimately mixed for 10 minutes. Finally, the magnesium stearate is added through a sieve of 0.8 mm width and, after mixing for a further 3 minutes, the mixture is introduced in portions of 140 milligrams each into size 0 (elongated) gelatin dry-fill capsules.
A 0.2% injection or infusion solution can be prepared, for example) in the following manner:
active ingredient 5.0 g sodium chloride 22.5 g phosphate buffer pH 7.4 300.0 g demineralized water to 2500.0 milliliters The active ingredient is dissolved in 1000 milliliters of water and f ltered through a microfilter. The buffer solution is added and the whole is made up to 200 milliliters with water.
To prepare dosage unit forms, portions of 1.0 or 2.5 milliliters each are introduced into class ampoules (each containing respectively 2.0 or 5.0 milligrams of active ingredient).
R= is -H. alkyl of I to 8 carbon atoms, benzy, pyridylmethyl, or alkoxymethyl;
R' is i) ethylene, ii) vinylene, iii) a branched alkylene of 3 to 10 carbon atoms, iv) a branched alkenylene of 3 to 10 carbon atoms, v) cycloalkylene of 4 to 9 carbon atoms unsubstituted or substituted with 1 or more substituents each selected independently from vitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy. carboxy, 10 hydroxy, amino, substituted amino alkyl of 1 to 6 carbon atoms. substituted amino acyl of 1 to 6 carbon atoms) alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 12 carbon atoms, or halo, vi) cycloalkenylene of 4 to 9 carbon atoms unsubstituted or substituted with I or more substituents each selected independently from vitro, cyano, trifluoromethyh carbethoxy, carbomethoxy. carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino alkyl of 1 to 6 carbon atoms, substituted amino acyl of I to 6 carbon atoms, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 12 carbon atoms, or halo, vii) o-phenylene unsubstituted or substituted with 1 or more substituents each selected independently from vitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl. carbamoyl, acetoxy, carboxy, hydroxy, amino. substituted amino alkyl of 1 to 6 carbon atoms, substituted amino acyl of 1 to 6 carbon atoms, alkyl of 1 to 10 carbon atoms.
alkoxy of 1 to 12 carbon atoms, or halo, viii) napthyl, or ix) pyridyl;
R4 is -CX-, -CH,- or -CH,CX-;
XisOorS;
and, n is 0,1,2, or 3.
A first preferred subclass of Formula II pertains to compounds in which R' is o-phenylene where:
R' is 3,4-diethoxyphenyl or 3-ethoxy-4-methoxyphenyl and R4 is -CO-, -CH,- or -CHzCO-.
Typical compounds of this invention include 3-phthalimido-3-(3',4'-dimethoxyphenyl)propan-1-ol;
2-phthalimido-2-(3',4'-dimethoxyphenyl)ethanol;
3-phthaIimido-3-(3'.4'-diethoxyphenyl)propan-1-ol;
3-phthalimido-3-(3',4'-dimethoxyphenyl)-I -methoxvpropane;
2-phthalimido-2-(3',4'-dimethoxyphenyl)-1-methoxyethane;
3-phthalimido-3-(3',4'-diethoxyphenyl)-1-methoxypropane;
3-phthalimido-3-(3',4'-dimethoxyphenyl)-1-ethoxypropane;
3-phthalimido-3-(3',4'-dimethoxyphenyl)-I-(3-pyridylmethoxy)propane;
3-phthalimido-3-(3',4'-diethoxyphenyl)-1-(3-pyridylmethoxyl)propane;
3-phthalimido-3-napthylpropan-1-ol;
3-phthalimido-3-(3',4'-diethylphenyl)propan-I-ol;
3-phthalimido-3-(3',4'-dipropylphenyl)propan-I -ol;
3-phthalimido-3-(3',4'-diethylphenyl)-1-methoxypropane;
3-phthalimido-3-(3',4'-diethoxyphenyl)-1-ethoxypropane;
3-phthalimido-3-cyclohexyl-1-methoxypropane;
3-phthalimido-3-(3',4'-diethylcyclohexyl)-I-methoxypropane;
3-(I'-oxoisoindolinyl)-3-(3',4'-dimethoxyphenyl)propan-1-ol;
2-( I'-oxoisoindolinyl)-2-(3',4'-dimethoxyphenyl)ethanol;
3-( I'-oxoisoindolinyl)-3-(3',4'-diethoxyphenyl)propan-1-ol;
-25 3-(1'-oxoisoindolinyl-3-(3',4'-dimethoxyphenyl)-1-methoxypropane;
2-(1'-oxoisoindolinyl)-2-(3',4'-dimethoxyphenyl)-I-methoxyethane;
_g_ WO 98/247b3 PCT/US97/22369 ~-(I'oxoisoindolinyl)-3-(3',4'-diethoxyphenyl)-1-methoxypropane;
3-( I'-oxoisoindolinyl)-3-(3',4'-dimethoxyphenyl)-I-ethoxypropane;
3-( 1'-oxoisoindolinyl)-3-(3',4'-dimethoxyphenyl)-I-(3-pyridylmethoxy)propane;
3-( 1'-oxoisoindolinyl)-3-(3',4'-diethoxyphenyl)-I -(3-pyridylmethoxyl)propane;
3-(1'-oxoisoindolinyl)-3-napthylpropan-I-ol;
3-( I'-oxoisoindolinyl)-3-(3',4'-diethylphenyl)propan-I-ol;
3-( 1'-oxoisoindolinyl)-3-(3',4'-dipropylphenyl)propan-1-ol;
3-( I'-oxoisoindolinyl)-3-(3',4'-diethylphenyl)-I -methoxypropane;
3-( 1'-oxoisoindoliny l)-3-(3',4'-diethoxyphenyl)- I -ethoxypropane.
3-phthalimido-3-(3'-ethoxv-4'-methoxyphenyl)propan-1-of 3-phthalimido-3-(3'-ethoxv-4'-methoxyphenyl)-I-methoxypropane 3-phthalimido-3-(3'-propoxy-4'-methoxyphenyl)propan-1-of 3-phthalimido-3-(3'-propoxy-4'-methoxyphenyl)-1-methoxypropanc 3-phthalimido-3-(3'-cyclopentoxy-4'-methoxyphenyl )propan-1-of 3-phthalimido-3-(3'-cyclopentoxy-4'-methoxyphenyl)-1-methoxypropanc 3-phthalimido-3-(3'-isopropoxy-4'-methoxyphenyl)propan-1-of 3-phthalimido-3-(3'-isopropoxy-4'-methoxyphenyl)-1-methoxypropane 3-phthalimido-3-(3'-ethoxy-4'-ethylphenyl)propan-1-of 3-phthalimido-3-(3'-ethoxv-4'-ethylphenyl)-1-meth~mprc~pam 3-( 1'-oxoisoindolinyl)-3-(3'-ethoxy-4'-methoxyphcw I ~- ; -mr;tww pr«pan:
3-( 1'-oxoisoindolinyl)-3-(3'-propoxy-4'-methoxypheny I ~propan- I -o I
3-( 1'-oxoisoindol inyl)-3-(3'-propoxy-4'-methoxyphenyl)- I -methoxypropane 3-( I'-oxoisoindolinyl)-3-(3'-cyclopentoxy-4'-methoxyphenyl)propan-I-of 3-( 1'-oxoisoindolinyl)-3-(3'-cyclopentoxy-4'-methoxyphenyl}-I-methoxypropane 3-( 1'-oxoisoindolinyl)-3-(3'-isopropoxy-4'-methoxyphenyl)propan-1-of 3-( I'-oxoisoindolinyl)-3-(3'-isopropoxy-4'-methoxyphenyl)-I-methoxypropane 3-( I'-oxoisoindolinyl)-3-(3'-ethoxy-4'-ethylphenyl)propan-I-of 3-( 1'-oxoisoindolinyl)-3-(3'-ethoxy-4'-ethylphenyl)-1-methoxypropane 3-(3-aminophthalimido)-3-(3'-ethoxy-4'-methoxyphenyl)-1-methoxypropane 3-(3-aminophthalimido)-3-(3'-propoxy-4'-methoxyphenyl)propan-1-of 3-(3-aminophthalimido)-3-(3'-propoxy-4'-methoxyphenyl)-1-methoxypropane 3-(3-aminophthalimido)-3-(3'-cyclopentoxy-4'-methoxyphenyl)propan-1-of 3-(3-aminophthalimido)-3-(3'-cyclopentoxy-4'-methoxyphenyl)-1-methoxypropane 3-(3-aminophthalimido)-3-(3'-isopropoxy-4'-methoxyphenyl)propan-1-of 3-(3-aminophthalimido)-3-(3'-isopropoxy-4'-methoxyphenyl)-1-methoxypropane 3-(3-aminophthalimido)-3-(3'-ethoxy-4'-ethylphenyl)propan-1-of 3-(3-aminophthalimido)-3-(3'-ethoxy-4'-ethylphenyl)-1-methoxypropane 3-(3-hydroxyphthalimido)-3-(3'-ethoxy-4'-methoxyphenyl)-1-methoxypropane 3-(3-hydroxyphthalimido)-3-(3'-propoxy-4'-methoxyphenyl)propan-1-of 3-(3-hydroxyphthalimido)-3-(3'-propoxy-4'-methoxyphenyl)-1-methoxypropane 3-(3-hydroxyphthalimido)-3-(3'-cyclopentoxy-4'-methoxyphenyl)propan-1-of 3-(3-hydroxyphthalimido)-3-(3'-cyclopentoxy-4'-methoxyphenyl)-1-methoxypropane 3-(3-hydroxyphthalimido)-3-(3'-isopropoxy-4'-methoxyphenyl)propan-1-of 3-(3-hydroxyphthalimido)-3-(3'-isopropoxy-4'-methoxyphenyl)-1-methoxypropane 3-(3-hydroxyphthalimido)-3-(3'-ethoxy-4'-ethylphenyl)propan-1-of 3-(3-hydroxyphthalimido)-3-(3'-ethoxy-4'-ethylphenyl)-1-methoxypropane 3-homophthalimido-3-(3'-ethoxy-4'-methoxyphenyl)-1-methoxypropane 3-homophthalimido-3-(3'-propoxy-4'-methoxyphenyl)propan-1-of 3-homophthalimido-3-(3'-propoxy-4'-methoxyphenyl)-1-methoxypropane 3-homophthalimido-3-(3'-cyciopentoxy-4'-methoxyphenyl)propan-1-of 3-homophthalimido-3-(3'-cyclopentoxy-4'-methoxyphenyl)-1-methoxypropane 3-homophthaiimido-3-(3'-isopropoxy-4'-methoxyphenyl)propan-1-of 3-homophthalimido-3-{3'-isopropoxy-4'-methoxyphenyl)-1-methoxypropane 3-homophthalimido-3-(3'-ethoxy-4'-ethylphenyl)propan-1-of WO 9$!24763 PCT/US97/22369 3-homophthalimido-.i-(3'-ethoxy-4'-ethylphenyl)-1-methoxypropane 3-(4-aminophthalimido)-3-( 3'-ethoxy-4'-methoxypheny 1 )-1-methoxypropane 3-(4-aminophthalimido)-3-(3'-propoxy-4'-methoxyphenyl)propan-1-of 3-(4-aminophthalimido)-3-(3'-propoxv-4'-methoxyphenyl)-1-methoxypropane 3-(4-aminophthalimido)-3-(3'-cyclopentoxy-4'-methoxyphenyl)propan-1-of 3-(-i-aminophthalimido)-3-(3'-cyclopentoxy-4'-methoxyphenyl)-1-methoxypropane -3-(4-aminophthalimido)-3-(3'-isopropoxy-4'-methoxyphenyl)propan-1-of 3-(4-aminophthalimido)-3-(3'-isopropoxy-4'-methoxyphenyl)-1-methoxypropane 3-(4-aminophthalimido)-3-(3'-ethoxy-4'-ethylphenyl)propan-1-of 3-(-1-aminophthalimido)-3-(3'-ethoay-d'-ethylphenyl)-1-methoxypropane The temp alkyl as used herein denotes a univalent saturated branched or straieht hydrocarbon chain. Unless otherwise stated. such chains can contain from 1 to 18 carbon atoms. Representative of such alkyl groups are methyl. ethyl. propyl, isopropyl. butyl, isobutyl.
sec-bum!. tent-buy!, penwl.
isopenwl. neopentyl, tent-pentyl. hexyl. isohexyh heptyl, octyl. nonyl. decyl.
undecyl. dodecvl.
1~ tridecyl. tetradecyl. pentadecyl. hexadecyl. heptadecyh octadecyl, and the like. ~i'hen qualified by "lower". the alkyl group will contain from 1 to 6 carbon atoms. The same carbon content applies to the parent term "alkane" and to derivative terms such as "alkoxv".
The compounds can be used, under the supewision of qualified professionals, to inhibit the undesirable effects of TlrFa. The compounds can be administered orally, rectallv, or parenterallv.
?0 alone or in combination with other therapeutic agents including antibiotics. steroids. etc.. to a mammal in need of treatment. Oral dosage forms include tablets, capsules, dragees) and similar shaped. compressed pharmaceutical forms. Isotonic saline solutions containing ?0-100 milligrams/milliliter can be used for parenteral administration which includes intramuscular.
intrathecal, intravenous and infra-arterial routes of administration. Rectal administration can be effected through the use of suppositories formulated from conventional carriers such as cocoa butter.
Dosage regimens must be titrated to the particular indication, the age.
weight. and general physical condition of the patient, and the response desired but generally doses will be from about 1 to about 500 milligrams/day as needed in single or multiple daily administration. In general, an initial treatment regimen can be copied from that known to be effective in interfering with TNFa activity for other TNFa mediated disease states by the compounds of the present invention. Treated individuals will be regularly checked for T cell numbers and T4/T8 ratios and/or measures of viremia such as levels of reverse transcriptase or viral proteins, and/or for progression of cytokine-mediated disease associated problems such as cachexia or muscle degeneration. If no effect is found following the normal treatment regimen, then the amount of cytokine activity interfering agent administered is increased, e.g., by fifty percent a week.
The compounds of the present invention also can be used topically in the treatment or prophylaxis of topical disease states mediated or exacerbated by excessive TNFa production.
respectively, such as viral infections, such as those caused by the herpes viruses, or viral conjunctivitis) etc.
The compounds also can be used in the veterinary treatment of mammals other than humans in need of prevention or inhibition of TNFa production. TNFa mediated diseases for treatment.
therapeutically or prophylactically, in animals include disease states such as those noted above. but in particular viral infections. Examples include feline immunodeficiency virus. equine infectious anaemia virus, caprine arthritis virus, visna virus, and mac~ii virus. as w.li as other lentiviruses Certain of these compounds possess eentrr~ c~t vh~talm an;'. car exist as optical i,c~mrr~
Both the racemates of these isomers and the indimdua! m~m:w th:msclyes. as well as dias:err«mr,-.
when there are two chiral centers, are within the scope of the present invention. The racerratr~ can be used as such or can be separated into their individual isomers mechanically as by chromatography using a chiral absorbant. Alternatively, the individual isomers can be prepared in chiral form or separated chemically from a mixture by forming salts with a chiral acid, such as the individual enantiomers of Z O-camphorsulfonic acid, camphoric acid, alpha-bromocamphoric acid.
methoxyacetic acid, tartaric acid, diacetyltartaric acid, malic acid, pyrrolidone-5-carboxylic acid, and the like, and then freeing one or both of the resolved bases, optionally repeating the process, so as to obtain either or both substantially free of the other; i. e., in a form having an optical purity of >95%.
Prevention or inhibition of production of TNFa by these compounds can be conveniently assayed using anti-TNFa antibodies. For example, plates (Nunc lmmunoplates, Roskilde, DK) are treated with 5 pg/milliliter of purified rabbit anti-TNFa antibodies at 4°C for 12 to 14 hours. The plates then are blocked for 2 hours at 25°C with PBS/0.0~% Tween containing milligrams/milliliter BSA. After washing, 100 gL of unknowns as well as controls are applied and the plates incubated at 4°C for 12 to 14 hours. The plates are washed and assayed with a conjugate of peroxidase (horseradish) and mouse anti-1'NFa monoclonal antibodies, and the color developed with o-phenylenediamine in phosphate-citrate buffer containing 0.012% hydrogen peroxide and read at 492 nm.
The compounds can be prepared using methods v~~hich are known in general for the preparation of imides. A preferred general reaction scheme includes the reaction of a substituted amine with an appropriate anhydride. Other synthetic methods known in the art may be used, for example. phthalimido compounds are made by reacting the substituted amine with either phthalic anhydride, N-carbethoxyphthalimide, or phthalic dicarboxaldehyde as illustrated by the formulas:
O O
II RN H., A P~C~O + Ph\C NR
Ip O
O O
P~C~NCOzEt + RN HZ ----~ Ph'C j R
I o Ph'C H + RNH, ---~ ptr~O NR
I_H Ci O
q q R3'Ci0 + RN HZ ~ R3\CiN R
D) R' q R' R3~~ NQ + CH ORS --~ C\
2)n R3~ N--\R4~ X ~Ra~ ~CHz)nOR=
RN H
F ~ O + 2 --~ PtrC~NR
CHZ ~ CH_-O O
The following examples will serve to further typify the nature of this invention but should not be construed as a limitation in the scope thereof; which scope is defined solely by the appended claims.
3-Amino-3-(3',4'-dimethoxyphenyf)propionic acid A stirred suspension of 3,4-dimethoxybenzaldehyde (131 grams, 788 mmol) and ammonium acetate (121.5 grams, 1576 mmol) in ethanol (9~%, 400 mL) was heated to 45-50 °C resulting in an orange solution. To this solution was added malonic acid (82.0 grams, 788 mmol) and the solution was refluxed overnight. A white solid precipitated on heating, the slurry was allowed to cool to room temperature and was filtered. The solid was washed with ethanol, air dried.
and dried in vacuo (60°C, < 1 mm) to afford 3-amino-3-(3',4'-dimethoxyphenyl)propionic acid as a white solid, (100.14 grams, 56% yield), no further purification was carried out: mp 208.0-210.0 °C; 'H NMR
(D~O/NaOD/TSP) 8 7.08-6.91 (m, 3H), 4.22 (t, J= 7 Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 2.55 (dd, J= 2, 7Hz, 2H); "C NMR (D~O/NaOD/TSP) 8 182.9, 150.8. 149.8, 140.7, 121.6, 114.6. 112.8, 58.6, 55.4, 49.8.
Methyl 3-amino-3-(3',4'-dimethoxyphenyl)propionate.
To a stirred suspension of 3-amino-3-(3', 4'-dimethoxyphenyl)propionic acid (70.1 grams, 312 mmol) in methanol (400 mL) at 0 °C, was added acetyl chloride (47.6 mL, 667 mmol) dropwise.
After an additional 1 ~ minutes, the ice-water bath was removed. The resulting clear solution was stirred at room temperature for 2 hours. The system was opened and the solvent was blown off with N, overnight. To the solid was added methanol (50 mL) and ether (300 mL). The resulting suspension was stirred at room temperature for I hour. The suspension was filtered and the solid . 10 was washed with ether (100 mL). The solid was dissolved in a mixture of sodium carbonate (200 mL, sat), water (300 mL), and methylene chloride (2~0 mL). The organic layer was separated. The aqueous layer was extracted with methylene chloride (3 X 2~0 mL). The combined organic layers were dried over magnesium sulfate. Removal of solvent gave methyl 3-amino-3-{3'.4'-dimethoxyphenvl)propionate as an oil (60.2 grams. 81% yield): 'H NMR (CDCI_) b 1.77 (s, 2H, 1~ NH,), 2.65 (d, J= 7 Hz, 2H, CH_), 3.68 (s. 3H, CH;), 3.87 (s, 3H, CH;).
3.89 (s. 3H. CH;). 4.39 (t, J = Hz. 1 H. Cl~. 6.81-6.93 (m. 3H, Ar); 'rC NIvIR (CDCI;) 8 44.00. ~ 1.48, X2.18. ».72. ».76.
109.20, 111.02, 118.02. 137.21. 148.1 l, 1-18.93, 172.34; Anal. Calcd for C,=H,,NO, 0.1 H,O C, X9.19; H, 7.19; N, x.81. Found: C, 59.38; H, 7.09; N, 5.91.
20 3-Amino-3-(3',4'-dimethoxyphenyl)-propan-1-ol.
A solution of 3-amino-3-(3',4'-dimethoxyphenyl)-propionate (4.12 grams. 17.2 mmol) in methanol (~0 milliliters) was slowly added to stirred sodium borohydride (6.51 grams, 17.2 mmol). After the initial effervescence had ceased the mixture was refluxed for 1 hour. Reaction progress was monitored by TLC (20% ethyl acetate/hexane, uv) and was complete after 1 hour.
The reaction mixture was allowed to cool and then 20 milliliters of water was added. The methanol was removed in vacuo resulting in the formation of a gum which was extracted into methylene chloride (3 X 20 milliliters). The combined extracts were dried over magnesium sulfate and concentrated to afford an oil which was refrigerated. A waxy solid formed which was dried in vacuo (60 oC , < 1 ~) to afford 3.30 g (86%) of the product as a white solid. 'H NMR (CDCI3) S 6.91-6.78(m , 3H), 4.15-4.04(m , 1H), 3.89(s , 3H), 3.88{s , 3H), 3.84-3.71(s , 2H), 3.91-2.45(broad m , 1H), 1.95-1.78(m , 2H).
3-Amino-3-(3', 4'-dimet6oxypheayl)-1-propanol To a stirred solid of sodium borohydride (94.18 grams, 2.49 mol) at 0 °C. was added methanol (50 mL). To this mixture at 0 °C was added a solution of methyl 3-amino-3-{3', 4'-dimethoxyphenyl)propionate (S9.S grams, 249 mmol) in methanol (9S0 mL) over 1 hour. The mixture was stirred in that ice-water bath until the temperature of the reaction mixture staved at 3S
1S °C or lower for 30 minutes. (Caution: If the ice-water bath was removed too early, a highly exothermic reaction may occur.) The water bath was then removed and the solution was refluxed for 16 hours. The solution was allowed to cool to room temperature. To the solution was added water {300 mL), followed by methylene chloride (2S0 mL) at 0 °C. The resulting suspension was filtered. Half of the filtrate was removed in vacuo. The resulting solution was dissolved in methylene chloride (S00 mL) and water (300 mL). The organic layer was separated. The aqueous layer was extracted with methylene chloride (3 X 500 mL). The combined organic layers were washed with brine ( 100 mL), and dried over magnesium sulfate. Removal of solvent gave an oil.
The resulting oil was dried in vacuo to afford 3-amino-3-(3',4'-dimethoxvphenyl)-1-propanol as a white solid (42.15 grams, 80% yield): mp 63.5-65.5 °C;'H NMR (CDC1,) 8 6.91-6.78(m , 3H), 4.15-4.04(m , 1H), 3.89(s , 3H), 3.88(s , 3H), 3.84-3.71(s , 2H), 2.91-2.4~(m , 1H), 1.95-1.78(m , 2H); Anal Calcd for C"H"N03: C, 62.54; H, 8.11; N, 6.63. Found: C, 62.01; H, 7.80; N, 6.49.
3-Phthalimido-3-(3',4'-dimethoxyphenyl)propan-1-ol.
A mixture of 3-amino-3-(3',4'-dimethoxyphenyl)-propan-1-of (1.11 grams, ~
mmol) and phthalic anhydride (0.74 grams, 5 mmol) were melted together and stirred for 5 minutes.
After cooling, a green/yellow glassy semi solid formed which was stirred in ether to afford 1.62g (95°io) of crude product as a white solid. The crude product was purified by flash chromatography (silica gcl. 40%
ethyl acetate/methylene chloride) to afford 1.25 grams (73%) of product as a white solid. 'H NMR
(CDCI;) 5 7.8~-7.63 (m , 4 H), 7.18-7.07 (m , 2 H), 6.86-6.76 (m , 1 H), x.62-5.49(m , 1 1-i), 3.88 (s , 3 H), 3.85 (s , 3 H), 3.79-3.63 (m , 2 H), 2.89-2.71 (m . 1 H), 2.64-2.47 {m , I H), 1.87-1.73 (br m , 1 H). '' C NMR (CDCI;) 8 168.x, 148.8, 148.6, 133.9, 131.8, 131.7, 123.2, 1 ?0.7, I 11.6, 1 I 0.8, 59.8, 5~.0, 55.8, 51.4, 33.9. Anal. Calcd. for C,9H,9N05. Theoretical : C
,66.85 ; 1-I , 5.61 : N , 4.10.
Found : C,66.70 ; H , 5.60 ; N , 4.06. HPLC 100%.
13 3-Amino-3-(3'-ethoxy-4'-methoxyphenyl)propionic acid A stirred mixture of 3-ethoxy-4-methoxybenzaldehyde ( 119.5 grams, 664 mmol ) and ammonium acetate ( 148.3 grams, 1.92 mol) in ethanol (300 mL, 95%) was heated at 45 °C. To the mixture was added malonic acid (69 grams, 664 mmol), followed by ethanol (100 mL, 95%).
The mixture was refluxed for 18 hours. The mixture was cooled to room temperature and was stirred for 2 hours. The suspension was filtered and the solid was washed with cold ethanol (5 x ~0 mL) to give 3-amino-3-(3'-ethoxy-4'-methoxyphenyl)propionic acid as a white solid, which was dried in a vacuum oven overnight, (94.7 grams, 60% yield): mp, 224.0-225.5 °C;'H NMR
(D,O/NaOD) 8 1.41 (t, J= 7 Hz, 3H, CH3}, 2.52-2.56 {m, 2H, CHz), 3.83 (s, 3H, CH;), 4.14 (q, J= 7 Hz, 2H, CH,), 4.19 (t, J=
WO 98/24763 PCT/US97/223b9 7 Hz, 1 H, NCH), 6.98-7.04 (m, 3H, Ar); "C NMR (D~O/NaOD) 8 16.75, 49.81, 55.45, X8.46) 67.63, 114.17, 114.71, 121.76, 140.69, 149.91, 150.09, 182.97; Anal. Calcd for C,ZH"NO,: C, 60.24; H.
7.16; N, 5.85. Found: C, 60.21; H, 7.12; N, 5.88.
Methyl3-amino-3-(3'-ethoxy-4'-methoxyphenyl)propionate.
To a stirred suspension of 3-amino-3-(3'-ethoxy-4'-methoxyphenyl)propionic acid (89.47 grams.
374.4 mmol) in methanol (500 mL) at 0 °C, was added acetyl chloride (~4 mL, 757 mmol) dropwise.
After 1 ~ minutes, the ice-water bath w.~as removed. The resulting clear solution was stirred at room temperature for 2 hours. The system was opened and the solvent was blown off with :~i~ overnight.
To the solid was added methanol (50 mL) and ether {300 mL). The resulting suspension was stirred at room temperature for 1 hour. The suspension was filtered and the solid was washed with ether ( 100 mL). The solid was dissolved in a mixture of sat aqueous sodium carbonate (200 mL), water (200 mL), and methylene chloride (2~0 mL). The organic layer was separated.
The aqueous layer was extracted with methylene chloride (3 X 2~0 mL). The combined organic layers were dried over magnesium sulfate. Removal of solvent gave methyl 3-amino-3-(3'-cyclopentoxy-4'-methoxyphenyl)propionate as an oil (80.84 grams, 85% yield): 'H~NMR (CDCI;) 8 1.46 (t, J= 7 Hz, 3H, CH;), 1.75 (s, 2H, NHz), 2.64 (d, J= 7 Hz, 2H, CH,), 3.68 (s, 3H, CH3), 3.86 (s, 3H, CH;), 4.10 (q, J= 7 Hz, 2H, CHZ), 5.36 (t, J= 7 Hz, 1H, NCH), 6.80-6.91 (m, 3H, Ar);
''C NMR (CDCI;) b 14.74, 44.09, 51.55, 52.23, 55.91, 64.23, 110.77, 111.39, 118.07, 137.21, 148.31, 148.49, 172.44.
3-Amino-3-(3'-ethoxy-4'-methoxyphenyl)-1-propanol To a stirred solid of sodium borohydride (121 grams, 3.19 mol) at 0 °C, was added methanol {50 mL). To this mixture at 0 °C was added a solution of methyl 3-amino-3-(3 ~-ethoxy-4'-methoxyphenyl)propionate (80.84 grams, 319.5 mmol) in methanol (1500 mL) over 1 hour. The mixture was stirred in that ice-water bath until the temperature of the reaction mixture stayed at 35 °C or lower for 30 minutes. (Early removal of the ice bath may result in a highly exothermic reaction). The water bath was then removed and the solution was refluxed for 16 hours. The solution was allowed to cool to room temperature. To the solution was added water (300 mL).
followed by methylene chloride (250 mL) at 0 °C. The resulting suspension was filtered. Half of the filtrate was removed in vacuo. The resulting solution was dissolved in methylene chloride (500 mL) and water (300 mL). The organic layer was separated. The aqueous layer was extracted with methylene chloride (3 X S00 mL). The combined organic layers were washed with brine (100 mL), and dried over magnesium sulfate. Removal of solvent gave an oil. The resulting oil was dried in vacuo to afford 3-amino-3-{3'-ethoxy-4'-methoxyphenyl)-1-propanol as a white solid (~3 grams.
74% yield): 'H NMR (CDCl3) 8 1.47 (t, J= 6.8 Hz, 3H, CH;), 1.84-1.90 (m, 2H, CH ). 2.58 (br s.
3H) NH=, OH). 3.78 (t, J= 5.5 Hz, 2H, OCH~), 3.86 {s, 3H, CH;), 4.04-4.15 (m, 3H, CH , NCH).
6.84 (s. 3H, Ar); ''C NMR (CDCI;) 8 14.74, 39.78, 55.84, 5.91, 61.86, 64.28, I10.5~, 111.47, 1~ 117.8, 138.82. 148.27, 148.32; Anal. Calcd for C,,H,9N03: C, 63.98; H, 8.50; N, 6.22. Found: C.
63.73; H, 8.44: N, 6.14.
3-(3'-Ethoxy-4'-methoxyphenyl)-3-phthalimido-I-propanol A mixture of 3-amino-3-(3'-ethoxy-4'-methoxyphenyl)-1-propanol (8.4 grams, 37.3 mmol) and sodium carbonate (3.95 grams, 37.3 mmol) in acetonitrile and water (40 mL
each) was stirred at room temperature for 15 minutes. To the solution was added N-carbethoxyphthalimide (8.18 grams, 37.3 mmol) as solid. After 20 minutes, the acetonitrile was removed under vacuum. The aqueous solution was extracted with methylene chloride (3 X 50 mL). The combined organic layers were washed with HCl (40 mL, 1N), and dried over magnesium sulfate. Removal of solvent gave a green ?5 oil. Ether (2~ mL) was added to the oil, then hexane (2 mL) was added. A
suspension formed and the solid m~as filtered to give 3-(3'-ethoxy-4'-methoxyphenyl)-3-phthalimido-1-propanol as a white solid, 1 g. The mother liquor was purified by chromatography (silica gel 500grams, 10, 15, 20%
EtOAc/CH~CI,) to give 3-(3'-ethoxy-4'-methoxyphenyl)-3-phthalimido-1-propanol as a solid, 2.54 g. Total yield was 3.54 g (27% yield): mp, 112.0-114.0 °C; 'H NMR
(CDCI;) 8 I .45 (t, J= 7 Hz, 3H, CH3), 1.59-1.65 (br s, 1H, OH), 2.49-2.59 (m, IH, CHH), 2.71-2.83 (m, IH, CHH)) 3.66-3.69 (m, 2H, OCH:), 3.84 (s, 3H, CH3), 4.10 (q, J= 7 Hz, 2H, MeCI-~ ), 5.53 (dd. J
= 6.5. 9.5 fIz, 1 H, NCH), 6.81 (d, J = 8.2 Hz, 1 H, Ar), 7.09-7.27 (m, 2H, Ar), 7.66-7.72 (m, 2H, Ar), 7.76-7.82 (m, 2H, Ar}; '3C NMR (CDCI,) 8 14.72, 33.86, 51.46, 55.88, 59.84, 64.34, 111.16, 113.05. 120.68, 123.20, 131.64, 131.86, 133.94, 148.17, 148.97, 168.49; Anal Calcd for C2°H,,NOS: C. 67.59: I-I, 5.96; N.
3.94. Found: C, 65.40; H, 5.8 i ; N, 3.84.
3-Amino-3-(3-cyclopenh~loxy-4-methoxyphenyl)propionic acid A stirred mixture of 3-cyclopentyloxy-4-methoxybenzaldehyde (54.9 grams) 249 mmol) and ammonium acetate (58.2 grams, 748 mmol) in ethanol (200 mL, 95%) was heated to 45 °C. To the yellowish suspension, was added malonic acid (25.9 grams, 249 mmol) as a solid. The mixture was refluxed for lb h. The mixture was cooled to room temperature. The suspension was filtered and the solid was washed with cold ethanol (200 mL) until the color was removed.
The ~~hite solid was dried in a vacuum oven (45 °C, 1 torr) to afford 3-amino-3-(3'-cyclopentoxy-4'-methoxyphenyl)propionic acid as white solid (41.97 grams, 61% yield): mp, 234.0-235.0 °C; 'H
NMR (CDC13) b 1.62-1.98 (m, 8H, CSHB), 2.53 (d, J= 7 Hz, 2H, CI~), 3.80 (s, 3H, CI~), 4.21 (t, J= 7 Hz, 1 H, OCH), 4.84-4.86 (m, 1 H, NCH), 6.96-7.03 (m, 3H, Ar); "C NMR
(CDC1;) b 26.33, 34.97, 49.78, 55.32, 58.48, 83.99, 114.99, I 16.04, 121.63, 140.63, 149.12, 150.75, I82.87; Anal Calcd for C,SHZ,NOa: C, 64.50; H, 7.58; N, 5.01. Found: C, 64.54; H, 7.68; N, 4.93.
Methyl 3-amino-3-(3'-cyclopentoxy-4'-methoxyphenyl)propionate To a stirred suspension of 3-amino-3-(3'-cyclopentyloxy-4'-methoxyphenyl)propionic acid (30 grams, 279 mmol) in methanol ( 1 ~ 0 mL) at 0 °C, was added acetyl chloride ( 15.2 mL, 212 mmol) dropwise. After 15 minutes, the ice-water bath was removed. The resulting clear solution was stirred at room temperature for 2h. The system was opened and the solvent was blown off with N
overnight. To the solid was added methanol (50 mL) and ether (300 mL). The resulting suspension was stirred at room temperature for 1 h. The suspension was filtered and the solid was washed with ether ( 100 mL,). The solid was dissolved in a mixture of aqueous sodium carbonate (200 mL, sat), water (200 mL), and methylene chloride (250 mL). The organic layer was separated. The aqueous layer was extracted with methylene chloride (3 X 250 mL). The combined organic la~~ers were dried over magnesium sulfate. Removal of solvent gave methyl 3-amino-3-(3'-cyclopentoxy-4'-methoxyphenyl)propionate as an oil (28.41 grams, 90% yield): 'H NMR (CDCI;) 8 1.~6-1.97 (m, IOH, NH,, CSHB). 2.62 (d, J= 7 Hz, 2H, CH,), 3.67 (s, 3H, CH;), 3.81 (s, 3H, CH;), 4.34 (t, J= 6.8 Hz. 1 H, CH), 4.74-4.79 (dd, J = 5, 8.5 Hz, 1 H, NCH), 6.78-6.90 (m, 3H, Ar);
''C NMR (CDC1;) 8 23.97, 32.76, 44.17, 51.58, 52.25, 56.07, 80.37, 111.96, 113.08, 119.08, 137.2, 147.72, 149.27, 172.49.
3-Amino-3-(3'-cyclopenh~ioxy-4'-methoxyphenyl)-1-propanol To a stirred solid of sodium borohydride (37 grams, 978 mmol) at 0 °C, was added methanol (50 mL). To this mixture at 0 °C was added a solution of methyl 3-amino-3-(3'-cyclopentyloxy-4'-methoxyphenyl)propionate {27 grams, 92.2 mmol) in methanol (500 mL) over 1 h.
The mixture was stirred in that ice-water bath until the temperature of the reaction mixture stayed at 35 °C or lower for 30 minutes. (Caution: If the ice-water bath was removed too early, a highly exothermic reaction may occur.) The water bath was then removed and the solution was refluxed for 16h. The solution was allowed to cool to room temperature. To the solution was added water ( I
25 mL), followed by methylene chloride (250 mL) at 0 °C. The resulting suspension was filtered. ~Ialf of the filtrate was removed in vacuo. The resulting solution was dissolved in methylene chloride (250 mL) and water (200 mL). The organic layer was separated. The aqueous layer was extracted with methylene chloride (3 X 250 mL). The combined organic layers were washed with brine ( 100 mL), and dried over magnesium sulfate. Removal of solvent gave an oil. The resulting oil was dried in vacuo to afford 3-amino-3-(3'-cyclopentyloxy-4'-methoxyphenyl)-1-propanol as a white solid (22.3 grams, 91% yield): mp, 216.0-217.5 °C; 'H NMR (CDCI;) 8 1.52-1.68 (m, 2H, CHZ), 1.76-1.91 (m, 8H, C5H8), 2.92 (brs, 3H, NHz, OH), 3.76 (t, J= 5.5 Hz. 2H, CH=}. 3.82 (s, 3H, CH3), 4.06 (t, J= Hz, I H, OCH), 4.76-4.79 (m, 1 H, NCH), 6.82-6.84 (m, 3H, Ar); '= C NMR (CDCI;) b 23.96, 32.75, 39.91, 55.59, 56.10, 61.62. 80.46, 112.11, 112.99, 117.75, 138.65. 147.74, 149.12; Anal Calcd for C,SH,;N03 0.05 CH,C1~: C, 67.05; H, 8.64, N, 5.20. Found: C. 67.02; H, 8.41;
N, 5.08.
3-(3'-Cyclopentyloxy-4'-methoxyphenyl)-3-phthalimido-1-propanol A mixture of 3-amino-3-(3'-cyclopentyloxy-4'methoxyphenyl}-1-propanol (4.31 grams, 16.24 mmol) and phthalic anhydride (2.41 grams. 16.27 mmol) was melted vvth a heat gun for 6 minutes.
The mixture was allowed to cool to room temperature. Chromatography (silica gel 100 grams. 1:5 EtOAc:CHzCl2) gave 3-(3'-cyclopentyloxy-4'-methoxyphenyl)-3-phthalimido-1-propanol as solid.
(4.97 grams, 77% yield): mp, 59.0-61.0 °C; 'H NMR (CDCl3) S 1.56-I .98 (m, 9H, OH, C ~ll~l, 2.48-2.59 (m, 1H, CHIC, 2.71-2.83 (m, 1H, CHH), 3.b6-3.74 (m, 2H, OCH,), 3.80 (s, 3H, CH;), 4.74 4.80 (m, 1 H, CH), 5.51 (dd, J = 6.5, 9.4 Hz, I H, NCH), 6.78 (d, J = 8.3 Hz, 1 H, Ar), 7.05-7.09 (m, 1 H, Ar), 7.16-7.17 (m, 1 H, Ar), 7.64-7.70 (m, 2H, Ar), 7.75-7.81 (m, 2H, Ar); "C NMR (CDCI;) 8 24.02, 32.71, 38.84, 51.44, 55.94, 59.75, 80.35, I I I .58, I 15.06, 120.54, 123.12, 131.60, 131.80, 133.86, 147.48, 149.55, 168.43; Anal Calcd for C~;Hz5N05: C, 69.86; H, 6.37;
N, 3.54. Found: C, 69.51; H, 6.41; N, 3.54.
3-(3'-Ethoxy-4'-methoxyphenyl)-3-(3"-nitro-phthalimido)-1-propanol A mixture of 3-amino-3-(3'-ethoxy-4'methoxyphenyl)-1-propanol (4.0 grams, 17.8 mmol) and 3-nitrophthalic anhydride (3.44 grams, 19.8 mmol) was melted with a heat gun for 6 minutes. The mixture was allowed to cool to room temperature. Chromatography (silica gel 80 grams, 1:5 EtOAc:
CH,CI_) gave 3-(3'-ethoxy-4'-methoxy)phenyl-3-(3"-nitro-phthalimido)-1-propanol as a yellow solid, (3.67 grams, 52% yield): mp, 143.0-145.0 °C; 'H NMR (CDCI;) b 1.47 (t, J= 7Hz, 3H, CHI.
I .48-I .52 (brs, 1 H. OH), 2.51-2.62 (m, 1 H, CHH), 2.72-2.84 (m, 1 H, CHH), 3.69-3.73 (m, 2H, CH,), 3.85 (s, 3H, CH;), 4.12 (q, J= 7 Hz, 2H, CH,), 5.56 (dd, J= 6.~, 9 Hz, 1H, NCN), 6.82 (d, J= 8 Hz, 1 H, Ar), 7. I I -7.15 (m, 2H, Ar), 7.85-7.91 (m, I H, Ar), 8.06-8.09 (m, 2H, Ar); ''C NMR (CDCI;) ~ 14.71, 33.51, 52.61, 55.91, 59.87, 64.43, 111.26, 113.08, 120.91, 123.52.
126.91. 128.43, 130.82, 133.97. 13.21, 145.13, 148.27, 149.25, 163.02, 165.97; Anal Calcd for C:°H,°N,O,: C. 60.00; H, 5.03; N, 7.00. Found: C, 59.83; H, 4.97; N, 6.86.
3-(3"-Amino-phthalimido)-3-(3'-ethoxy-4'-methoxyphenyl)-I-propanol A mixture of 3-(3'-ethoxy-4'-methoxyphenyl)-3-(3"-nitro-phthalimido)-1-propanol (600 mg, 1.~
mmol) and Pd/C (100 mg, 10%) in ethyl acetate (40 mL) was shaken under hydrogen (~0 psi) for 16h. The mixture was filtered through a pad of celite. Removal of solvent and chromatography (silica gel 80 grams, 1:3 EtOAc:CH,CI,) gave 3-(3"-amino-phthalimido)-3-(3'-ethoxy-4'-methoxyphenyl)-1-propanol as a yellow solid, (495 mg, 89% yield): mp, 81.0-83.0 °C; 'H NMR
(CDCI;) 8 1.45 (t, J= 6.8 Hz, 3H, CH3), 1.80 (brs., IH, OH), 2.45-2.52 (m, 1H, CHH), 2.71-2.80 (m, 1H, CHH), 3.66-3.75 (m, 2H, OCH,), 3.84 (s, 3H, CH,), 4.09 (q, J= 6.8 Hz, 2H, CH,), 5.23 (br s, 2H, I~TH,), 5.47 (dd, J= 6.4, 9.8 Hz, 1H, CH)) 6.78-6.83 (m, 2H, Ar), 7.07-7.13 (m, 3H, Ar), 7.33-7.39 (m, 1 H, Ar); ''C NMR (CDC13) 8 14.72, 33.92. 50.79, 55.87, 59.76, 64.34, 111.03. 111.14.
112.01, 113 .07, I 20.52, 121.60, 131.94, 132.49, 13 5.09, 145.24, 148. I 1, 148.84, 168.76, 170.31;
Anal Calcd for C,oH~,N~05: C, 64.85; H, 5.99; N, 7.56. Found: C, 64.44; H, 6.I4; N, 6.88.
3-(3'-Ethoxy-4'-methoxyphenyl)-3-(3',4',5',6'-tetrahydrophthalimidoyl)-1-propanol A mixture of 3-amino-3-(3'-ethoxy-4'-methoxyphenyl)-1-propanol (4.0 grams, 17.7~mmo1) and 3.4,5,6-tetrahydrophthalic anhydride (2.80 grams, 18.4 mmol) was melted with a heat gun for 6 minutes. The mixture was allowed to cool to room temperature. Chromatography (silica eel 150 grams, 1:3 EtOAc:CH,CI,) gave 3-(3'-ethoxy-4'-methoxyphenyl)-3-(3',4',5',6'tetrahydrophthalimidoyl)-1-propanol as an oil, (4.96 grams. 75%
yield): 'I-I NMR
(CDCI;) 8 1.45 (t, J= 6.8 Hz, 3H, CHI, 1.70-1.80 (m. 4H, CH= CH~1. 1.91 (brs, 1H, OtT), 2.27-'?.32 (m, 4H, CH,. CH,), 2.41-2.58 (m, 1 H, CHI7), 2.61-2.68 (m, I H. CI-ill). 3.59-3.65 (m, 2I-I. CN 1. 3. f~-i (s. 3H, CH;), 4.09 (q, J= 6.9 Hz, 2H, CH,), 5.26 (dd..l = 6.6, 9.5 Hz. 1 H, NCH), 6.79 (d. .l = 8 Hz.
1 H, Ar), 7.00-7.09 (m, 2H, Ar); '3C NMR (CDCl3) 8 14.64, 19.83, 21.19, 34.10, 50.90, 55.79. 59.6.
64.24, 111.04, 112.86, 120.41, 132.11, 141.28, 148.01. 148.7 3. 171.19: Anal Calcd for C,;,I-I:.NO.
C, 66.84; H. 7.01; N, 3.90. Found: C, 66.89; 1-I. 6.R4: l~. ~ 7 EXAMPL.F 17 3-(3',4'-Dimethoxyphenyl)-3-(1'-oxoisoindolinyl)-1-propanol To a stirred suspension of 3-(3',4'-dimethoxyphenyl)-3-(1'-oxoisoindolinyl)propionic acid (3.7.1 grams, 10.96 mmol) in THF (60 mL) at -10-15 °C (ice-salt bath), was added borane in THF ( 1 1 mL.
1 M, 11 mmol). The suspension was allowed to warm to room temperature slowly overnight. To the resulting clear solution was added water (20 mL), followed by potassium carbonate (6 g). The organic layer was separated. The aqueous layer was extracted with methylene chloride (2 X 50 mL).
The combined organic layers were washed with sodium carbonate (20 mL, sat), brine (20 mL), and dried over magnesium sulfate. Removal of solvent and chromatography (silica gel, 100 grams, 1:2, I:1 EtOAc/CH,C12) gave 3-(3',4'-dimethoxyphenyl}-3-(1'-oxoisoindolinyl)-I-propanol as an oil, (2.52 grams, 70%). Ether (6 mL) and 2 drops of methanol were added to the oil.. Hexane was added until the solution was turned cloudy. The mixture was stirred for 30 minutes to give a white solid and the solid was filtered: mp, 101.5-103.0 °C; 'H NMR (CDC13) b 1.99-2.36 (m, 3H, CH,, OH), 3.49-3 . 80 (m, 2H, OCHz), 3.86 (s, 3 H, CHI, 3.89 (s, 3 H, CH ~, 3 .91 (d, J
= 17.2 Hz, 1 H, CHl~, 4.19 (d, J = 17.2 Hz, 1 H, CHH), 5.75 (dd, J = 4, 11.5 Hz, 1 H, NCH), 6.86-7.00 (m, 3 H, Ar), 7.27-7.56 (m, 3H, Ar), 7.86-7.89 (m, 1 H, Ar); "C NMR (CDC13) 8 33.87, 46.22, 50.61, 55.91, 56.01, 58.56, 111.04, 111.73. 119.66, 122.81, 123.89, 128.64, 131.33, 131.66, 132.09, 141.35, 148.81, 148.24.
I 69.46; Anal Calcd for C,9Hz,N0,: C, 69.71; H, 6.47; N, 4.28. Found: C, 69.51; H. 6.27; N, 4.12.
3-{3',4'-Dimethoxyphenyl)-1-methoxy-3-phthalimidopropane To a solution of 3-(3',4'-dimethoxyphenyl)-3-phthalimido-1-propanol (1.02 grams, 2.99 mmol) and IS methyl iodide (0.37 mL, 5.94 mmol) in THF (10 mL) at room temperature, was added NaH (358 mg, 60%. 8.96 mmol). The mixture was stirred at room temperature for 46 minutes.
and then was retluxed for 2h. To the cooled mixture was added a few drops of NH4C1, then HC1 (1N, 26 mL).
The organic layer was separated. The aqueous layer was extracted with ethyl acetate (3 X 26 mL).
The combined organic layers were washed with brine (26 mL), and dried over magnesium sulfate.
Removal of solvent and chromatography (silica gel 100 grams, 1:5 EtOAc:hexane) gave 3-(3',4'-dimethoxyphenyl)-1-methoxy-3-phthalimidopropane as a white solid, (750 mg, 71%
yield): mp, 91.5-92.5 °C; 'H NMR (CDCI,) 8 2.50-2.59 (m, 1H, CHH), 2.70-2.86 (m, IH, CHH), 3.27 (s, 3H, CH;), 3.39 (t, J= 6 Hzr2H, CHI, 3.85 (s, 3H, CHI, 3.88 (s, 3H, CH), 5.49 (dd, J= 6.8, 9.2 Hz, 1H, NCH), 6.81 (d, J = 8 Hz, 1 H, Ar), 7.11-7. I 5 (m, 2H, Ar), 7.67-7.72 (m, 2H, Ar), 7.77-7.83 (m, 2H, Ar); "C NMR (CDC13) 8 31.29, 51.93, 55.80, 58.69, 69.64, 110.84, 115.56, 120.62, 123.12, 131.90, WO 98/24763 PCTlUS97/22369 1332.03, 133.84, 148.58, 148.81, 168.38; Anal Calcd for Cz°H,,NOS: C, 67.59; H, 5.96: N, 3.94.
Found: C, 67.54; H, 5.97; N, 3.84.
3-{3'-Ethoxy-4'-methoxyphenyl)-1-methoxy-3-phthalimidopropane.
To a stirred mixture of sodium hydride (110 mg, 60%, 2.75 mmol) in THF (8 mL) at room temperature, was added iodomethane (0.54 grams, 3.78 mmol) followed by 3-(3'-ethoxy-4'-methoxyphenyl)-3-phthalimido-1-propanol (850 mg, 2.39 mmol). The mixture was stirred at room temperature for 15h. To the mixture was added NHaCI (20 mL, sat). The organic layer was separated. The aqueous layer was extracted with methylene chloride (2 X 50 mL). The combined organic layers were washed with brine {50 mL) and dried over magnesium sulfate. Removal of solvent and chromatography (silica gel 200 grams, 1:12 EtOAc:CH=C1,) gave 3-(3'-ethoxy-4'-methoxyphenyl)-I-methoxy-3-phthalimidopropane as an oil (360 mg. 41% yield).
The resulting oil solidified after standing at room temperature over weekend: mp, 67.5-70.0 °C; 'H NMR (CDCI;) 8 I .45 (t, J = 7 Hz, 3 H, CH3), 2.50-2.60 (m, 1 H, CHH), 2.71-2.85 (m, 1 H, CHH), 3.26 (s, 3 H, CH;), i 5 3.3 9 (t, J = 6 Hz, 2H, CH,), 3 .84 (s, 3 H, CH3), 4.10 (q, J = 7Hz, 2H, CH,), 5.47 {dd. J = 7, 9.3 Hz, 1 H, NCH), 6.81 (d, J = Hz, 1 H, Ar), 7.09-7.16 (m, 2H, Ar), 7.66-7.69 (m, 2H, Ar), 7.76-7.82 (m, 2H, Ar). '3C NMR (CDCI;) 8 (APT) 14.67 (CI-~ ), 31.23 (CI-h ), 51.89 (CI-~ ), 58.63 (CH), 64.25 (CH,), 69.62 (CH,), 111.13 (CH), 112.98 (CH), 120.58 (CH), 123.06 (CH), 131.87 (C), 131.92 (C), 133.78 (CH), 148.09 (C), 148.84 (C), 168.33 (C); Anal Calcd for C,,H,3N05 0.05 H=O: C, 67:66;
H, 6.23; N, 3.75. Found: C, 67.91; H, 6.00; N, 3.71.
3-(3'-Cyclopentyloxy-4'-methoxyphenyl)-1-methoxy-3-phthalimidopropane.
To a solution of 3-(3'-cyclopentyloxy-4'-methoxyphenyl)-3-phthalimido-1-propanol (786 mg, 1.99 mmol) and methyl iodide (0.25 mL, 4.0 mmol) in THF (10 mL) at room temperature, was added NaH { I 60 mg, 60%, 4.0 mmol). The mixture was stirred at room temperature for I h, and then was refluxed for 35 minutes. The mixture was allowed to cool to room temperature.
To the resulting mixture was added a few drops ofNH4Cl, then HCl (1N, 25 mL). The organic layer was separated.
The aqueous layer was extracted with ethyl acetate (3 X 30 mL). The combined organic layers were washed with brine (25 mL), and dried over Na,S04. Removal of solvent and chromatography (silica gel 100 grams, 1:5 EtOAc:hexane) gave 3-(3'-cyclopentyloxy-4'-methoxyphenyl)-1-methoxy-3-phthalimidopropane as an oil, (510 mg, 63% yield). The oil solidified upon standing at room temperature to give a white solid: mp, 77.5-80.0 °C; 'H NMR (CDCI,) 8 1.58-1.96 (m, 8H, CSHB), 2.45-2.55 (m, 1 H, CHI, 2.70-2.85 (m, I H, CHH), 3.26 (s, 3H, CH3), 3.39 (t, J= 6 Hz, 2H, CH,), 3.81 (s, 3H, CH,), 4.78-4.80 (m, I H, OCH), 5.46 (dd, J= 7, 9.3 Hz, 1 H, NCH), 6.79 (d, J = 8.3 Hz, 1 H. Ar), 7.06-7.10 (m, 1 H, Ar), 7.17-7.26 (m, 1 H, Ar), 7.67-7.69 (m, 2H, Ar), 7.78-7.82 (m, 2 H, Ar); ''C NMR (CDC13) 8 24.08, 31.30, 32.76, 51.94, 56.00, 58.71, 69.71, 80.37, 111.63, 115.09.
120.53, 123.12. 131.92, 131.96, 133.81, 147.53, 149.55, 169.37; Anal Calcd for C,,H_,NOS: C.
70.40; H, 6.65; N, 3.42. Found: C, 70.32; H, 6.61; N, 3.31.
I-Ethoxy-3-(3'-ethoxy-4'-methoxyphenyi)-3-phthalimidopropane.
To a stirred solution of 3-(3'-ethoxy-4'-methoxypheny!)-3-phthalimido-1-propanol (1 gram, 2.82 mmol), ethyl bromide (0.42 mL, 5.63 mmol), and tetrabutyl ammonium iodide (200 mg, 0.54 mmol) in THF ( 10 mL) at room temperature, was added NaH (270 mg, 60%, 6.75 mmol).
The mixture was stirred at roam temperature for 45 minutes, and then was heated to reflux for 4h. To the mixture was added a few drops ofNH~CI, then HCl (1N, 25 mL). The organic layer was separated. The aqueous layer was extracted with ethyl acetate (3 X 25 mL). The combined organic layers were washed with brine (25 mL), and dried over magnesium sulfate. Removal of solvent and chromatography (silica gel 100 grams, 1:5 EtOAc:hexane) gave 1-ethoxy-3-(3'-ethoxy-4'-methoxyphenyl)-phthalimidopropane as an oil, (800 mg, 74% yield): 'H NMR (CDCI3) 8 1.06 (t, J= 7Hz, 3H, CH;), 1.46 (t, J= 7 Hz, 3H, CH;), 2.46-2.58 (m, 1H, CHH), 2.75-2.95 (m, IH, CHH), 3.37 (q, J= 7 Hz, 2H, CHz),.3.44 (q, J= 7 Hz, 2H, CH,), 3.85 (s, 3H, CH,), 4.12 (q, J= 7 Hz, 2H, CH,), 5.49 (dd, J
= 6.4, 9.5 Hz, I H, NCH), 6.81 (d, J = 8.2 Hz, 1 H, Ar), 7.10-7.48 (m, 2H, Ar), 7.68-7.72 (m, 2H, Ar), 7.77-7.83 (m, 2H, Ar); '3C NMR (CDCI;) 8 14.73, 14.98, 31.31, 52.24, 55.89, 64.30. 66.33, 67.73, I I 1. I 1 ( 1 I 2.99, 120.61, 123. I 1, 132.00, 132.09, 13 3.80, 148.11, 148.84. 168.44; Anal Calcd for Cz2H,~N05: C, 68.91; H, 6.57; N, 3.65. Found: C, 68.77; H, 6.47; N, 3.57.
1-Benzyloxy-3-(3'-ethoxy-4'-methoxyphenyl)-3-phthalimidopropane To a stirred solution of 3-(3'-ethoxy-4'-methoxyphenyl)-3-phthalimido-1-propanol (680 mg, 1.92 mmol), benzyl bromide (0.46 ml,, 3.86 mmol), and tetrabutyl ammonium iodide (80 mg. 0.21 mmol) in THF (20 mL,) at room temperature, was added NaH (240 mg, 60%, 6.0 mmol).
The mixture was stirred at room temperature for 15h. To the mixture was added a few drops of NH~CI. then HCI ( 1 N, 25 mL). The organic layer was separated. The aqueous layer was extracted with ethyl acetate (3 X
25 mL). The combined organic layers were washed with brine (25 mL), and dried over magnesium sulfate. Removal of solvent and chromatography (silica gel 100 grams, 1:5 EtOAc:hexane) gave 1-benzyloxy-3-(3'-ethoxy-4'-methoxyphenyl)-3-phthalimidopropane as an oil, (510 mg. 60% yield):
'H NMR (CDCI,) 8 1.46 (t, J= 6.9 Hz, 3H, CH ), 2.51-2.59 (m, TH, CHI-, 2.86-2.96 (m, 1H, CHH), 3.51 (t, J = 5.5 Hz, CH~), 3.85 (s, 3 H, CH3 ), 4.10 (q, J = 7 Hz, CHZ
), 4.43 (s, 2H, PhCl~ ).
5.54 (dd, J = 6.5, 9.5 Hz, 1 H, NCH), 6. 80 (d, J = 8 Hz, 1 H, Ar), 7.09-7.27 (m, 7H, Ar), 7.65-7.79 (m. 4H, Ar); ''C NMR (CDC13) b 14.73, 31.37, 52.12, 55.88, 64.29, 67.31, 73.10, 1 I 1.11, 1 i 2.95, 120.59, 123.09, 127.42, 127.62, 128.22, 131.92, 132.09, 133.77, 138.09, 148.12, 148.84, 168.42;
Anal Calcd for C,,H,,NOS: C, 72.79; H, 6.11; N, 3.14. Found: C, 72.66; H, 6.32; N, 3.16.
WO 98/24763 PCTlUS97/22369 3-(3',4'-Dimethoxyphenyl)-I-ethoxy-3-(1'-oxoisoindolinyl)propane To a stirred solution of 3-(3',4'-dimethoxyphenyl)-3-(1'-oxoisoindolinyl)-I-propanol (500 mg, 1.53 mmol), ethyl bromide (0.27 mL, 3.62 mmol) and tetrabutyl ammonium iodide (60 mg, 0.16 mmol) in THF ( 10 mL) at room temperature, was added NaH ( 160 mg, 60%, 4.0 mmol).
The mixture was stirred at room temperature for 4h. To the mixture was added NH4C1 (20 mL, sat). The organic layer was separated. The aqueous layer was extracted with methylene chloride (2 X 2~ mL). The combined organic layer was dried over magnesium sulfate. Removal of solvent and chromatography (silica gel 120 grams, 1:6 EtOAc:CH,CI,) gave 3-(3',4'-dimethoxyphenyl)-1-ethoxy-3-(1'-o~oisoindolinyl)propane as an oil, (420 mg, 77% yield): 'H NMR (CDCI;) 8 1.09 (t, ,I= 7Hz, 3H, CH;), 2.35-2.4~ (m, 2H, CH,), 3.35-3.58 (m, 4H, CH,OCH,), 3.84 (s, 3H, CH;), 3.86 (s, 3H, CH;).
4.00 (d, J = 16.8 Hz, 1 H, NCHH), 4.3 5 (d, J = 16.8 Hz, 1 H, NCHH), 5.66 (dd, J = 6, 9.3 Hz, 1 H) NCH). 6.82-6.98 (m, 3H, Ar), 7.35-7.53 (m) 3H, Ar), 7.84-7.88 (m, 1 H, Ar);
''C NMR (CDCI,) 8 1 x.02. 31.62, 4.82, ~ 1.~ 1. 5.82, X5.90, 66.39, 67.86, I 10.90, 111.27, 119.15, 122.68, 3 23.71.
127.86) 131.16, 1-32.28, 132.73, 141.28, 148.49, 149.08, 168.38; Anal Calcd for C,,H,SNO, 0.3 HBO:
C. 69.90; H, 7.1 ~; N, 3.88. Found: C, 69.69; H, 6.80; N, 3.73.
Tablets, each containing ~0 milligrams of active ingredient, can be prepared in the following manner:
Constituents (for 1000 tablets) active ingredient 50.0 g lactose 50.7 g wheat starch 7.5 g polyethylene glycol 6000 5.0 g talc 5.0 g magnesium stearate 1.8 g demineralized water q.s.
The solid ingredients are first forced through a sieve of 0.6 mm mesh width.
The active ingredient, the lactose, the talc, the magnesium stearate and half of the starch are then mixed. The other half of the starch is suspended in 40 milliliters of water and this suspension is added to a boiling solution of the polyethylene glycol in 100 milliliters of water. The resulting paste is added to the pulverulent substances and the mixture is granulated, if necessary with the addition of water. The granulate is dried overnight at 35 °C, forced through a sieve of 1.2 mm mesh width and compressed-to form tablets of approximately 6 mm diameter which are concave on both sides.
EXAMPLE 2~
Tablets, each containing 100 milligrams of active ingredient. can be prepared in the following manner:
Constituents (for 1000 tablets) active ingredient 100.0 g lactose 100.0 g wheat starch 47.0 L
magnesium stearate : 0 g All the solid ingredients are first forced throuLh ~ sieve ~,1 U t~ mm mesh width. The acuvc ingredient, the lactose, the magnesium stearate and half of the starch then are mixed. The other half of the starch is suspended in 40 milliliters of water and this suspension is added to 100 milliliters of boiling water. The resulting paste is added to the pulverulent substances and the mixture is granulated, if necessary with the addition of water. The granulate is dried overnight at 35 °C, forced through a sieve of 1.2 mm mesh width and compressed to form tablets of approximately 6 mm diameter which are concave on both sides.
Tablets for chewing, each containing 75 milligrams of active ingredient, can be prepared in the following manner:
Composition (for 1000 tablets) active ingredient 75.0 g mannitol 230.0 g lactose 1 X0.0 g talc 21.0 g glycine 12.5 g stearic acid 10.0 g saccharin l,j g 5% gelatin solution q,s.
All the solid ingredients are first forced through a sieve of 0.25 mm mesh width. The mannitol and the lactose are mixed, granulated with the addition of gelatin solution, forced through a sieve of 2 mm mesh width, dried at 50 °C and again forced through a sieve of 1.7 mm mesh width.
The active ingredient, the glycine and the saccharin are carefully mixed, the mannitol. the lactose granulate, the stearic acid and the talc are added and the whole is mixed thoroughly and compressed to form tablets of approximately 10 mm diameter which are concave on both sides and have a breaking groove on the upper side.
Tablets, each containing 10 milligrams of active ingredient, can be prepared in the following manner:
Coml osition (for 1000 tablets) active ingredient 10.0 g lactose 328.5 g corn starch 17,j g polyethylene glycol 6000 5.0 g talc 25.0 g magnesium stearate 4.0 g demineralized water q.s.
The solid ingredients are first forced throueh a sieve of 0.6 mm mesh width.
Then the active ingredient, lactose. talc, magnesium stearate and half of the starch are intimately mixed. The other half of the starch is suspended in 65 milliliters of water and this suspension is added to a boiling solution of the polyethylene glycol in 260 milliliters of water. The resulting paste is added to the pulverulent substances, and the whole is mixed and granulated, if necessary with the addition of water. The granulate is dried overnight at 35 °C, forced through a sieve of 1.2 mm mesh width and compressed to form tablets of approximately 10 mm diameter which are concave on both sides and have a breaking notch on the upper side.
Gelatin dry-filled capsules, each containing 100 milligrams of active ingredient. can be prepared in the following manner:
Composition (for 1000 capsules) active ingredient 100.0 g microcrystalline cellulose 30.0 g sodium lauryl sulphate 2.0 g magnesium stearate 8.0 g The sodium lauryl sulphate is sieved into the active ingredient through a sieve of 0.2 mm mesh width and the two components are intimately mixed for 10 minutes. The microcrystalline cellulose is then added through a sieve of 0.9 mm mesh width and the whole is again intimately mixed for 10 minutes. Finally, the magnesium stearate is added through a sieve of 0.8 mm width and, after mixing for a further 3 minutes, the mixture is introduced in portions of 140 milligrams each into size 0 (elongated) gelatin dry-fill capsules.
A 0.2% injection or infusion solution can be prepared, for example) in the following manner:
active ingredient 5.0 g sodium chloride 22.5 g phosphate buffer pH 7.4 300.0 g demineralized water to 2500.0 milliliters The active ingredient is dissolved in 1000 milliliters of water and f ltered through a microfilter. The buffer solution is added and the whole is made up to 200 milliliters with water.
To prepare dosage unit forms, portions of 1.0 or 2.5 milliliters each are introduced into class ampoules (each containing respectively 2.0 or 5.0 milligrams of active ingredient).
Claims (18)
- Claim 1. A composition having the formula:
wherein R1 is (i) straight, branched, or cyclic, unsubstituted alkyl of 1 to 12 carbon atoms: (ii) straight, branched, or cyclic, substituted alkyl of 1 to 12 carbon atoms;
(iii) phenyl; or (iv) phenyl substituted with one or more substituents each selected independently of the other from the group consisting of vitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino,acylamino, alkyl(dialkyl)amino, alkyl of 1 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, bicycloalkyl of 5 to 12 carbon atoms, alkoxy of 1 to 10 carbon atoms, cycloalkoxy of 3 to 10 carbon atoms, bicycloalkoxy of 5 to 12 carbon atoms, or halo;
R2 is -H, alkyl of 1 to 8 carbon atoms, benzy, pyridylmethyl, or alkoxymethyl:
R3 is i) ethylene, ii) vinylene, iii) a branched alkylene of 3 to 10 carbon atoms, iv) a branched alkenylene of 3 to 10 carbon atoms, v) cycloalkylene of 4 to 9 carbon atoms unsubstituted or substituted with 1 or more substituents each selected independently from vitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carbon, hydroxy, amino, substituted amino alkyl of 1 to 6 carbon atoms, substituted amino acyl of 1 to 6 carbon atoms, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 12 carbon atoms, or halo, vi) cycloalkenylene of 4 to 9 carbon atoms unsubstituted or substituted with 1 or more substituents each selected independently from vitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy. hydroxy, amino, substituted amino alkyl of 1 to 6 carbon atoms, substituted amino acyl of 1 to 6 carbon atoms, alkyl of 1 to carbon atoms, alkoxy of 1 to 12 carbon atoms, or halo, vii) .sigma.-phenylene unsubstituted or substituted with 1 or more substituents each selected independently from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino alkyl of 1 to 6 carbon atoms, substituted amino acyl of 1 to 6 carbon atoms, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 12 carbon atoms, or halo, viii) napthyl, or ix) pyridyl;
R4 is -CX-, -CH2- or -CH2CX-;
X is O or S;
and, n is 0, 1, 2, or 3. - Claim 2. The composition of claim 1 wherein R4 is -CO- and R1 is 3,4-diethoxyphenyl.
- Claim 3. The composition of claim 1 wherein R4 is -CO- and R1 is 3-ethoxy-4-methoxyphenyl
- Claim 4. The composition of claim 1 wherein R~ is -CO- and R~ is 3-cyclopentoxy-4-methoxyphenyl.
- Claim 5. The composition of Claim 1 wherein R1 is 3,4-dimethoxyphenyl.
- Claim 6. The composition of Claim 1 wherein R1 is 3-ethoxy-4-methoxyphenyl.
- Claim 7. The composition of Claim 1 wherein R1 is 3-isopropoxy-4-methoxyphenyl.
- Claim 8. The composition of Claim 1 wherein R1 is 3-cyclopentoxy-4-methoxyphenyl.
- Claim 9. The composition of Claim 1 wherein R1 is 3-ethoxy-4-ethylphenyl.
- Claim 10 The composition of claim 1 wherein R4 is -CO- and R1 is substituted phenyl.
- Claim 11 The composition of claim 1 wherein R4 is -CH2- and R1 is substituted phenyl.
- Claim 12 The composition of claim 1 wherein R4 is -CH2CO- and R1 is substituted phenyl.
- Claim 13 The method of reducing levels of TNF.alpha. in a mammal which comprises administering thereto an effective amount of a compound of claim 1.
- Claim 14 The method of reducing levels of TNF.alpha. in a mammal which comprises administering thereto an effective amount of a compound of the formula:
wherein R1 is (i) straight, branched, or cyclic, unsubstituted alkyl of 1 to 12 carbon atoms; (ii) straight, branched, or cyclic, substituted alkyl of 1 to 12 carbon atoms;
(iii) phenyl; or (iv) phenyl substituted with one or more substituents each selected independently of the other from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino,acylamino, alkyl(dialkyl)amino, alkyl of 1 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, bicycloalkyl of 5 to 12-carbon atoms, alkoxy of 1 to 10 carbon atoms, cycloalkoxy of 3 to 10 carbon atoms, bicycloalkoxy of 5 to 12 carbon atoms, or halo;
R2 is -H, alkyl of 1 to 8 carbon atoms, benzy, pyridylmethyl, or alkoxymethyl;
R3 is i) ethylene, ii) vinylene, iii) a branched alkylene of 3 to 10 carbon atoms, iv) a branched alkenylene of 3 to 10 carbon atoms, v) cycloalkylene of 4 to 9 carbon atoms unsubstituted or substituted with 1 or more substituents each selected independently from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino alkyl of 1 to 6 carbon atoms, substituted amino acyl of 1 to 6 carbon atoms. alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 12 carbon atoms, or halo, vi) cycloalkenylene of 4 to 9 carbon atoms unsubstituted or substituted with 1 or more substituents each selected independently from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino alkyl of 1 to 6 carbon atoms, substituted amino aryl of 1 to 6 carbon atoms, alkyl of 1 to carbon atoms. alkoxy of 1 to 12 carbon atoms, or halo, vii) o-phenylene unsubstituted or substituted with 1 or more substituents each selected independently from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino alkyl of 1 to 6 carbon atoms, substituted amino acyl of 1 to 6 carbon atoms, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 12 carbon atoms.
or halo, viii) napthyl, or ix) pyridyl;
R4 is -CX-, -CH,- or -CH2CX-;
X is O or S;
and, n is 0, 1, 2, or 3. - Claim 15. The method of inhibiting TNF.alpha.-activated retrovirus replication in a mammal which comprises administering thereto an effective amount of a compound according to claim 1.
- Claim 16. A pharmaceutical composition comprising an amount of a compound according to claim 1 effective upon single or multiple dosage to inhibit TNF.alpha..
- Claim 17. A pharmaceutical composition comprising an amount of a compound according to claim 2 effective upon single or multiple dosage to inhibit TNF.alpha..
- Claim 18. The method of inhibiting phosphodiesterases in a mammal which comprises administering thereto an effective amount of a compound of the formula:
wherein R1 is (i) straight, branched, or cyclic, unsubstituted alkyl of 1 to 12 carbon atoms; (ii) straight, branched, or cyclic, substituted alkyl of 1 to 12 carbon atoms;
(iii) phenyl; or (iv) phenyl substituted with one or more substituents each selected independently of the other from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino,acylamino, alkyl(dialkyl)amino, alkyl of 1 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, bicycloalkyl of 5 to 12 carbon atoms, alkoxy of 1 to 10 carbon atoms, cycloalkoxy of 3 to 10 carbon atoms, bicycloalkoxy of 5 to 12 carbon atoms, or halo;
R2 is -H, alkyl of 1 to 8 carbon atoms, benzy, pyridylmethyl, or alkoxymethyl;
R3 is i) ethylene, ii) vinylene, iii) a branched alkylene of 3 to 10 carbon atoms, iv) a branched alkenylene of 3 to 10 carbon atoms, v) cycloalkylene of 4 to 9 carbon atoms unsubstituted or substituted with 1 or more substituents each selected independently from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino alkyl of 1 to 6 carbon atoms, substituted amino acyl of 1 to 6 carbon atoms, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 12 carbon atoms, or halo, vi) cycloalkenylene of 4 to 9 carbon atoms unsubstituted or substituted with 1 or more substituents each selected independently from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino alkyl of 1 to 6 carbon atoms, substituted amino acyl of 1 to 6 carbon atoms, alkyl of 1 to carbon atoms, alkoxy of 1 to 12 carbon atoms, or halo, vii) o-phenylene unsubstituted or substituted with 1 or more substituents each selected independently from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino alkyl of 1 to b carbon atoms, substituted amino acyl of 1 to 6 carbon atoms, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 12 carbon atoms, or halo, viii) napthyl, or ix) pyridyl;
R4 is -CX-, -CH2- or -CH2CX-;
X is O or S;
and, n is 0, 1, 2, or 3.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/759,788 | 1996-12-03 | ||
US08/759,788 US5703098A (en) | 1994-12-30 | 1996-12-03 | Immunotherapeutic imides/amides |
PCT/US1997/022369 WO1998024763A2 (en) | 1996-12-03 | 1997-12-03 | Immunotherapeutic imides/amides as pde iv and tnf inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2273002A1 true CA2273002A1 (en) | 1998-06-11 |
Family
ID=25056962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002273002A Abandoned CA2273002A1 (en) | 1996-12-03 | 1997-12-03 | Immunotherapeutic imides/amides as pde iv and tnf inhibitors |
Country Status (13)
Country | Link |
---|---|
US (1) | US5703098A (en) |
EP (1) | EP0942902A2 (en) |
JP (1) | JP2001506611A (en) |
KR (1) | KR20000069374A (en) |
CN (1) | CN100372836C (en) |
AU (1) | AU735540B2 (en) |
CA (1) | CA2273002A1 (en) |
FI (1) | FI991187A (en) |
HU (1) | HUP0000232A3 (en) |
NZ (1) | NZ336713A (en) |
RU (1) | RU2177471C2 (en) |
SK (1) | SK73299A3 (en) |
WO (1) | WO1998024763A2 (en) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
EP0918746B1 (en) * | 1996-08-12 | 2003-04-09 | Celgene Corporation | Immunotherapeutic agents and their use in the reduction of cytokine levels |
WO1998052588A1 (en) * | 1997-05-21 | 1998-11-26 | Medion Research Laboratories Inc. | Therapeutic agents for respiratory diseases |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
PL200923B1 (en) | 1999-08-21 | 2009-02-27 | Nycomed Gmbh | SYNERGISTIC COMBINATION OF PDE INHIBITORS AND ß₂ ADRENOCEPTOR AGONIST |
US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
US6326388B1 (en) | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
US6699899B1 (en) * | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
US8030343B2 (en) | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US7491634B2 (en) * | 2006-04-28 | 2009-02-17 | Asm International N.V. | Methods for forming roughened surfaces and applications thereof |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7208516B2 (en) * | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US7276529B2 (en) * | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
KR20050000398A (en) * | 2002-04-12 | 2005-01-03 | 셀진 코포레이션 | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
MXPA04009997A (en) * | 2002-04-12 | 2004-12-13 | Celgene Corp | Modulation of stem and progenitor cell differentiation, assays, and uses thereof. |
NZ536908A (en) | 2002-05-17 | 2008-09-26 | Celgene Corp | Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient |
WO2004034962A2 (en) * | 2002-10-15 | 2004-04-29 | Celgene Corporation | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
US20040087558A1 (en) | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US7776907B2 (en) | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
CA2505003A1 (en) * | 2002-11-06 | 2004-05-27 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
CA2505131A1 (en) | 2002-11-06 | 2004-05-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
MXPA05005164A (en) * | 2002-11-18 | 2005-07-22 | Celgene Corp | Methods of using and compositions comprising (+)-3 -(3, 4-dimethoxy -phenyl)-3 -(1-oxo-1, 3-dihydro -isoindol -2-yl)- propionamide. |
US20040167199A1 (en) * | 2002-11-18 | 2004-08-26 | Celgene Corporation | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
EA200501548A1 (en) * | 2003-04-01 | 2006-02-24 | Апплайд Резеч Системз Арс Холдинг Н.В. | PHOSPHODYSTERASE INHIBITORS FOR INFERTILITY |
US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
EP1692128A1 (en) | 2003-11-19 | 2006-08-23 | Signal Pharmaceuticals LLC | Indazole compounds and methods of use thereof as protein kinase inhibitors |
WO2005102317A1 (en) * | 2004-04-23 | 2005-11-03 | Celgene Corporation | Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension |
US7244759B2 (en) | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
JP2008518924A (en) * | 2004-10-28 | 2008-06-05 | セルジーン・コーポレーション | Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury |
JP2011515469A (en) * | 2008-03-24 | 2011-05-19 | セルジーン コーポレイション | Psoriasis using cyclopropyl-N- {2-[(1S) -1- (3-ethoxy-4-methoxyphenyl) -2- (methylsulfonyl) ethyl] -3-oxoisoindoline-4-yl} carboxamide Or treatment of psoriatic arthritis |
CN102387798A (en) | 2009-02-10 | 2012-03-21 | 细胞基因公司 | Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management of tuberculosis |
KR20120084306A (en) * | 2009-10-09 | 2012-07-27 | 셀진 코포레이션 | Processes for the preparation of 2-(1-phenylethyl)isoindolin-1-one compounds |
US9408831B2 (en) | 2010-04-07 | 2016-08-09 | Celgene Corporation | Methods for treating respiratory viral infection |
AU2011268450B2 (en) | 2010-06-15 | 2015-07-16 | Amgen (Europe) GmbH | Biomarkers for the treatment of psoriasis |
EP2601950A1 (en) * | 2011-12-06 | 2013-06-12 | Sanofi | Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists |
US20170087129A1 (en) | 2014-05-16 | 2017-03-30 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
EP3157520B1 (en) | 2014-06-23 | 2019-09-04 | Celgene Corporation | Apremilast for the treatment of a liver disease or a liver function abnormality |
WO2017070291A1 (en) | 2015-10-21 | 2017-04-27 | Celgene Corporation | Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
TW332201B (en) * | 1995-04-06 | 1998-05-21 | Janssen Pharmaceutica Nv | 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives |
US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US5728845A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
-
1996
- 1996-12-03 US US08/759,788 patent/US5703098A/en not_active Expired - Lifetime
-
1997
- 1997-12-03 KR KR1019997005100A patent/KR20000069374A/en not_active IP Right Cessation
- 1997-12-03 AU AU55945/98A patent/AU735540B2/en not_active Ceased
- 1997-12-03 HU HU0000232A patent/HUP0000232A3/en unknown
- 1997-12-03 RU RU99113849/04A patent/RU2177471C2/en not_active IP Right Cessation
- 1997-12-03 WO PCT/US1997/022369 patent/WO1998024763A2/en not_active Application Discontinuation
- 1997-12-03 CN CNB971803234A patent/CN100372836C/en not_active Expired - Fee Related
- 1997-12-03 CA CA002273002A patent/CA2273002A1/en not_active Abandoned
- 1997-12-03 EP EP97952302A patent/EP0942902A2/en not_active Ceased
- 1997-12-03 JP JP52584498A patent/JP2001506611A/en not_active Ceased
- 1997-12-03 NZ NZ336713A patent/NZ336713A/en unknown
- 1997-12-03 SK SK732-99A patent/SK73299A3/en unknown
-
1999
- 1999-05-25 FI FI991187A patent/FI991187A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
FI991187A (en) | 1999-07-16 |
KR20000069374A (en) | 2000-11-25 |
HUP0000232A3 (en) | 2000-10-30 |
RU2177471C2 (en) | 2001-12-27 |
WO1998024763A3 (en) | 1998-08-06 |
NZ336713A (en) | 2001-02-23 |
CN100372836C (en) | 2008-03-05 |
JP2001506611A (en) | 2001-05-22 |
EP0942902A2 (en) | 1999-09-22 |
US5703098A (en) | 1997-12-30 |
HUP0000232A2 (en) | 2000-09-28 |
FI991187A0 (en) | 1999-05-25 |
SK73299A3 (en) | 1999-12-10 |
CN1254333A (en) | 2000-05-24 |
AU5594598A (en) | 1998-06-29 |
WO1998024763A2 (en) | 1998-06-11 |
AU735540B2 (en) | 2001-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5703098A (en) | Immunotherapeutic imides/amides | |
EP1004572B1 (en) | Amines as inhibitors of TNF alpha | |
AU717100B2 (en) | Novel immunotherapeutic aryl amides | |
AU709719B2 (en) | Substituted imides as TNF inhibitors | |
US5658940A (en) | Succinimide and maleimide cytokine inhibitors | |
EP0957091B1 (en) | Inhibitors of tumor necrosis factor alpha | |
WO1996020926A9 (en) | Substituted imides as tnf inhibitors | |
CA2208672C (en) | Immunotherapeutic imides/amides and their use for reducing levels of tnf.alpha. | |
NZ536287A (en) | Use of succinimide and maleimide cytokine inhibitors to reduce the levels of TNF in a mammal | |
CZ192999A3 (en) | Immunotherapeutic imides/amides as PDE and TNF inhibitors, pharmaceutical composition in which such imides/amides are comprised, method of reducing TNFalpha levels and inhibition method of phosphodiesterase in mammals | |
KR20040003045A (en) | IMMUNOTHERAPEUTIC IMIDES/AMIDES AND THEIR USE FOR REDUCING LEVELS OF TNFα |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |